107. Juvenile idiopathic arthritis Disease details / Clinical trials / Drug dev / DR info


Clinical trials : 447 Drugs : 297 - (DrugBank : 57) / Drug target genes : 52 - Drug target pathways : 146

Drugs and their primary sponsors and trial info
(1-3)-beta-D-Glucan (BDG) assay (Fungitell)   
   Centre Hospitalier Universitaire, Amiens
      2019   -   NCT03984669   France;
(1-3)-ß-D-Glucan (BDG) assay (Fungitell)   
   Centre Hospitalier Universitaire, Amiens
      2019   -   NCT03984669   France;
- SOLUZIONE INIETTABILE IN SIRINGHE PRE-RIEMPITE- USO SOTTOCUTANEO- SIRINGA PRERIEMPITA (0,4ML)- 2 SIRINGHE PRE-RIEMPITE + 2 TAMPONI IMBEVUTI DI ALCOOL   
   FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO
      2021   Phase 4   EUCTR2021-004031-86-IT   Italy;
0.4mL prefilled syringes   
   Bristol-Myers Squibb International Corporation
      2013   Phase 3   EUCTR2012-003195-39-IT   Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States;
      2013   Phase 3   EUCTR2012-003195-39-ES   Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States;
      2013   Phase 3   EUCTR2012-003195-39-DE   Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States;
      2013   Phase 3   EUCTR2012-003195-39-BE   Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States;
      -   Phase 3   EUCTR2012-003195-39-FR   Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States;
      -   -   EUCTR2012-003195-39-Outside-EU/EEA   Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States;
0.7mL prefilled syringes   
   Bristol-Myers Squibb International Corporation
      2013   Phase 3   EUCTR2012-003195-39-IT   Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States;
      2013   Phase 3   EUCTR2012-003195-39-ES   Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States;
      2013   Phase 3   EUCTR2012-003195-39-DE   Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States;
      2013   Phase 3   EUCTR2012-003195-39-BE   Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States;
      -   Phase 3   EUCTR2012-003195-39-FR   Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States;
      -   -   EUCTR2012-003195-39-Outside-EU/EEA   Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States;
1mL prefilled syringes   
   Bristol-Myers Squibb International Corporation
      2013   Phase 3   EUCTR2012-003195-39-IT   Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States;
      2013   Phase 3   EUCTR2012-003195-39-ES   Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States;
      2013   Phase 3   EUCTR2012-003195-39-DE   Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States;
      2013   Phase 3   EUCTR2012-003195-39-BE   Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States;
      -   Phase 3   EUCTR2012-003195-39-FR   Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States;
      -   -   EUCTR2012-003195-39-Outside-EU/EEA   Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States;
98-92-0   
   UMC Utrecht
      2019   Phase 1;Phase 2   EUCTR2018-002245-11-NL   Netherlands;
      -   Phase 1;Phase 2   EUCTR2016-003643-10-NL   Netherlands;
ABT-494   
   ABBVIE DEUTSCHLAND GMBH & CO. KG
      2019   Phase 1   EUCTR2018-000715-25-IT   Germany;Hungary;Italy;Spain;United States;
   AbbVie Deutschland GmbH & Co. KG
      2019   Phase 1;Phase 3   EUCTR2018-000715-25-ES   Germany;Hungary;Italy;Spain;United States;
      2019   Phase 1   EUCTR2018-000715-25-HU   Germany;Hungary;Italy;Spain;United States;
      2019   Phase 1   EUCTR2018-000715-25-DE   Germany;Hungary;Italy;Spain;United States;
ACZ885   
   NOVARTIS FARMA
      2009   -   EUCTR2008-008008-42-IT   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-005479-82-IT   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
   NOVARTIS FARMA S.p.A.
      2014   Phase 3;Phase 4   EUCTR2013-004867-29-IT   Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Hong Kong;Hungary;Israel;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;Sweden;Turkey;United States;
   NOVARTIS PHARMA AG
      2006   -   EUCTR2006-001834-42-IT   France;Italy;United Kingdom;
   Novartis
      2006   Phase 1/Phase 2   NCT00426218   Italy;
   Novartis Farmaceutica, S.A.
      2013   -   EUCTR2012-003054-92-ES   Argentina;Austria;Belgium;Brazil;Canada;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Peru;Poland;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
   Novartis Farmacéutica S.A.
      2009   Phase 3   EUCTR2008-005476-27-ES   Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Norway;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-008008-42-ES   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-005479-82-ES   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
   Novartis Farmacéutica, S.A.
      2014   Phase 3;Phase 4   EUCTR2013-004867-29-ES   Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Hong Kong;Hungary;Israel;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;Sweden;Turkey;United States;
   Novartis Pharma K.K.
      2015   Phase 3   JPRN-JapicCTI-152865   -
   Novartis Pharma S.A.S
      2014   Phase 4   EUCTR2014-002872-95-FR   France;
   Novartis Pharma Services AG
      2014   Phase 3;Phase 4   EUCTR2013-004867-29-SE   Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Hong Kong;Hungary;Israel;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;Sweden;Turkey;United States;
      2014   Phase 3;Phase 4   EUCTR2013-004867-29-NL   Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Hong Kong;Hungary;Israel;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;Sweden;Turkey;United States;
      2014   Phase 3;Phase 4   EUCTR2013-004867-29-HU   Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Hong Kong;Hungary;Israel;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;Sweden;Turkey;United States;
      2014   Phase 3;Phase 4   EUCTR2013-004867-29-DE   Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Hong Kong;Hungary;Israel;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;Sweden;Turkey;United States;
      2014   Phase 3;Phase 4   EUCTR2013-004867-29-BE   Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Hong Kong;Hungary;Israel;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;Sweden;Turkey;United States;
      2014   Phase 3;Phase 4   EUCTR2013-004867-29-AT   Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Hong Kong;Hungary;Israel;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;Sweden;Turkey;United States;
      2013   -   EUCTR2012-003054-92-CZ   Argentina;Austria;Belgium;Brazil;Canada;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Peru;Poland;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2013   -   EUCTR2012-003054-92-AT   Argentina;Austria;Belgium;Brazil;Canada;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Peru;Poland;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2010   -   EUCTR2008-008008-42-GR   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2008-008008-42-AT   Argentina;Austria;Belgium;Brazil;Canada;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Peru;Poland;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2010   -   EUCTR2008-005479-82-GR   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2008-005476-27-GR   Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2008-005476-27-GB   Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
      2009   Phase 3   EUCTR2008-005479-82-FR   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Norway;Spain;Sweden;United Kingdom;
      2009   Phase 3   EUCTR2008-005479-82-BE   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
      2009   Phase 3   EUCTR2008-005476-27-FR   Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Norway;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-008008-42-SE   Argentina;Austria;Belgium;Brazil;Canada;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Peru;Russian Federation;Spain;Swaziland;Sweden;Turkey;United Kingdom;United States;
      2009   -   EUCTR2008-008008-42-NL   Argentina;Austria;Belgium;Brazil;Canada;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Peru;Poland;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2009   -   EUCTR2008-008008-42-HU   Argentina;Austria;Belgium;Brazil;Canada;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Peru;Poland;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2009   -   EUCTR2008-008008-42-GB   Argentina;Austria;Belgium;Brazil;Canada;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Norway;Peru;Poland;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2009   -   EUCTR2008-008008-42-FR   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-008008-42-DK   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-008008-42-DE   Argentina;Austria;Belgium;Brazil;Canada;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Norway;Peru;Poland;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2009   -   EUCTR2008-008008-42-BE   Argentina;Austria;Belgium;Brazil;Canada;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Peru;Poland;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2009   -   EUCTR2008-005479-82-SE   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-005479-82-HU   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-005479-82-GB   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-005479-82-DK   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-005479-82-DE   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-005479-82-AT   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-005476-27-SE   Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-005476-27-HU   Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-005476-27-DK   Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-005476-27-DE   Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-005476-27-BE   Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
      -   Phase 3   EUCTR2012-003054-92-BE   Argentina;Austria;Belgium;Brazil;Canada;Czech Republic;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Peru;Poland;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      -   Phase 3   EUCTR2008-008008-42-NO   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom;
      -   Phase 3   EUCTR2008-005479-82-NO   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Norway;Spain;Sweden;United Kingdom;
      -   Phase 3   EUCTR2008-005476-27-NO   Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Norway;Spain;Sweden;United Kingdom;
      -   -   EUCTR2008-005479-82-Outside-EU/EEA   Argentina;Brazil;Canada;Israel;Peru;Switzerland;Turkey;United States;
      -   -   EUCTR2008-005476-27-Outside-EU/EEA   Argentina;Brazil;Israel;Peru;Switzerland;Turkey;United States;
   Novartis PharmaServices AG
      -   -   EUCTR2008-008008-42-Outside-EU/EEA   Argentina;Brazil;Canada;Israel;Peru;Russian Federation;South Africa;Switzerland;Turkey;United States;
   Novartis Pharmaceuticals
      2013   Phase 3   NCT01676948   Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
ACZ885 150 mg (Canakinumab)   
   Novartis Pharmaceuticals
      2014   Phase 3   NCT02296424   Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Hong Kong;Hungary;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;Sweden;Turkey;United States;
ACZ885 Drug Substance   
   Novartis Pharma Services AG
      2007   Phase 2   EUCTR2006-001834-42-GB   France;Italy;United Kingdom;
      2007   -   EUCTR2006-001834-42-FR   France;Italy;United Kingdom;
ACZ885G   
   NOVARTIS FARMA
      2009   -   EUCTR2008-005476-27-IT   Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
AIN457   
   NOVARTIS PHARMA AG
      2019   Phase 3   EUCTR2018-002521-30-IT   Belgium;Germany;Italy;Poland;Russian Federation;South Africa;Spain;Turkey;United States;
      -   Phase 3   EUCTR2016-003761-26-IT   Belgium;Germany;Italy;Netherlands;Poland;Spain;Turkey;United Kingdom;United States;
   Novartis Farmacéutica S.A.
      2017   Phase 3   EUCTR2016-003761-26-ES   Belgium;Germany;Italy;Netherlands;Poland;Russian Federation;South Africa;Spain;Turkey;United Kingdom;United States;
   Novartis Farmacéutica, S.A.
      2019   Phase 3   EUCTR2018-002521-30-ES   Belgium;Germany;Italy;Poland;Russian Federation;South Africa;Spain;Turkey;United States;
   Novartis Pharma AG
      2019   Phase 3   EUCTR2018-002521-30-DE   Belgium;Germany;Italy;Poland;Russian Federation;South Africa;Spain;Turkey;United States;
      2017   Phase 3   EUCTR2016-003761-26-PL   Belgium;Germany;Italy;Poland;Russian Federation;South Africa;Spain;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-003761-26-GB   Belgium;Germany;Italy;Poland;Russian Federation;South Africa;Spain;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-003761-26-DE   Belgium;Germany;Italy;Poland;Russian Federation;South Africa;Spain;Turkey;United Kingdom;United States;
      2017   Phase 3   EUCTR2016-003761-26-BE   Belgium;Germany;Italy;Poland;Russian Federation;South Africa;Spain;Turkey;United Kingdom;United States;
      -   Phase 3   EUCTR2018-002521-30-PL   Belgium;Germany;Italy;Poland;Russian Federation;South Africa;Spain;Turkey;United States;
      -   Phase 3   EUCTR2018-002521-30-BE   Belgium;Germany;Italy;Poland;Russian Federation;South Africa;Spain;Turkey;United States;
   Novartis Pharmaceuticals
      2019   Phase 3   NCT03769168   Belgium;Germany;Italy;Poland;Russian Federation;South Africa;Spain;Turkey;United States;
      2017   Phase 3   NCT03031782   Belgium;Germany;Italy;Poland;Russian Federation;South Africa;Spain;Turkey;United Kingdom;United States;
AIN457F   
   NOVARTIS PHARMA AG
      -   Phase 3   EUCTR2016-003761-26-IT   Belgium;Germany;Italy;Netherlands;Poland;Spain;Turkey;United Kingdom;United States;
AMG-407   
   Amgen Inc.
      2021   Phase 3   EUCTR2019-002788-88-NL   Austria;Belgium;France;Italy;Netherlands;
      2021   Phase 3   EUCTR2019-002788-88-FR   Austria;Belgium;France;Netherlands;
      -   Phase 3   EUCTR2019-002788-88-PL   Austria;Belgium;France;Italy;Netherlands;Poland;
      -   Phase 3   EUCTR2019-002788-88-BE   Austria;Belgium;Netherlands;
      -   Phase 3   EUCTR2019-002788-88-AT   Austria;Belgium;France;Italy;Netherlands;
AMG407   
   AMGEN INC.
      2021   Phase 3   EUCTR2019-002788-88-IT   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;
   Amgen Inc.
      2021   Phase 3   EUCTR2019-002788-88-NL   Austria;Belgium;France;Italy;Netherlands;
      2021   Phase 3   EUCTR2019-002788-88-FR   Austria;Belgium;France;Netherlands;
      -   Phase 3   EUCTR2019-002788-88-PL   Austria;Belgium;France;Italy;Netherlands;Poland;
      -   Phase 3   EUCTR2019-002788-88-BE   Austria;Belgium;Netherlands;
      -   Phase 3   EUCTR2019-002788-88-AT   Austria;Belgium;France;Italy;Netherlands;
APD421   
   Pfizer Inc
      2012   Phase 2;Phase 3   EUCTR2011-004915-22-SK   Argentina;Australia;Belgium;Brazil;Canada;China;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
   Pfizer Inc, 235 East 42nd Street, New York, New York 10017
      2018   Phase 2;Phase 3   EUCTR2011-004915-22-BE   Argentina;Australia;Belgium;Brazil;Canada;China;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      -   Phase 2;Phase 3   EUCTR2011-004915-22-SE   Argentina;Australia;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
   Pfizer Inc.
      2020   Phase 3   EUCTR2017-002018-29-SK   Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
   Pfizer Inc. 235 East 42nd Street, New York, New York 10017
      2022   Phase 3   EUCTR2017-002018-29-HU   Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2017-002018-29-NL   Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2017-002018-29-DE   Argentina;Belgium;Brazil;Canada;Chile;China;Eritrea;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2017-002018-29-PL   Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      -   Phase 3   EUCTR2017-002018-29-SE   Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      -   Phase 3   EUCTR2017-002018-29-BE   Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
Abalimumab bio-originatore   
   FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO
      2021   Phase 4   EUCTR2021-004031-86-IT   Italy;
Abatacept   
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2016   Phase 3   EUCTR2016-000312-15-FR   France;
   Assistance Publique - Hôpitaux de Paris
      2017   Phase 3   NCT02840175   France;
   Bristol-Myers Squibb
      2013   Phase 3   NCT01844518   Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States;
      2013   Phase 3   NCT01835470   Japan;
   Bristol-Myers Squibb K.K.
      2013   Phase 3   JPRN-JapicCTI-132119   Japan;
   Yokohama City University Hospital Department of Pediatrics
      2016   -   JPRN-UMIN000024178   Japan;
Abatacept Injection   
   Duke University
      2019   Phase 3   NCT03841357   United States;
Actemra   
   F. Hoffmann-La Roche Limited
      2008   -   EUCTR2007-000872-18-SK   Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2007-000872-18-ES   Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2007-000872-18-DK   Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
Actemra, MRA   
   F. Hoffmann-La Roche Limited
      -   Phase 3   EUCTR2007-000872-18-NO   Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Norway;Slovakia;Spain;Sweden;United Kingdom;
Adalimumab   
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2016   Phase 3   EUCTR2016-000312-15-FR   France;
   AbbVie
      2008   -   NCT00783510   Australia;Austria;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Norway;Portugal;Puerto Rico;Slovakia;Spain;Sweden;United States;
   AbbVie (prior sponsor, Abbott)
      2009   Phase 3   NCT00775437   Czech Republic;Denmark;France;Germany;Puerto Rico;Slovakia;Sweden;United States;
   Assistance Publique - Hôpitaux de Paris
      2017   Phase 3   NCT02840175   France;
   ELI LILLY & COMPANY, LILLY CORPORATE CENTER
      2020   Phase 3   EUCTR2018-000681-10-IT   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
   Eli Lilly and Company
      2021   Phase 3   NCT04527380   Argentina;Belgium;Czechia;Denmark;France;Germany;Italy;Mexico;Netherlands;Spain;Switzerland;United Kingdom;
      2019   Phase 3   NCT04088409   France;Germany;Italy;Spain;United Kingdom;
   F.I. Proctor Foundation, University of California San Francisco
      2019   Phase 4   EUCTR2019-000412-29-GB   Australia;United Kingdom;United States;
   Nisha Acharya
      2020   Phase 4   NCT03816397   Australia;United Kingdom;United States;
Adalimumab (20mg)   
   University Hospitals Bristol NHS Foundation Trust
      2011   Phase 2   EUCTR2010-021141-41-GB   United Kingdom;
Adalimumab (40mg)   
   University Hospitals Bristol NHS Foundation Trust
      2011   Phase 2   EUCTR2010-021141-41-GB   United Kingdom;
Adalimumab biosimilare   
   FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO
      2021   Phase 4   EUCTR2021-004031-86-IT   Italy;
Alfacalcidol 2 micrograms/ml   
   Belfast Health and Social Care Trust, Musgrave Park Hospital
      2006   Phase 4   EUCTR2005-003129-23-GB   United Kingdom;
Ambirix   
   Public Health Service Amsterdam
      2009   -   EUCTR2008-003280-40-NL   Netherlands;
Anakinra   
   ISTITUTO GIANNINA GASLINI
      2005   -   EUCTR2005-004008-36-IT   Italy;
   Institut National de la Santé Et de la Recherche Médicale, France
      2006   Phase 2/Phase 3   NCT00339157   France;
   Swedish Orphan Biovitrum
      2019   -   NCT03932344   Italy;
Anakinra / kineret   
   University Medical Center Utrecht
      2016   Phase 4   EUCTR2015-004393-16-NL   Netherlands;
Anti-TNF   
   University of Sao Paulo
      2008   Phase 4   NCT02196480   Brazil;
Anti-pandemic H1N1 influenza vaccine   
   University of Sao Paulo
      2010   Phase 4   NCT01151644   Brazil;
Anti-tumor necrosis factor alpha monoclonal antibody   
   Assistance Publique - Hôpitaux de Paris
      2011   Phase 2/Phase 3   NCT01385826   France;
Antivirale ad uso diretto   
   Swedish Orphan Biovitrum AG
      -   Phase 2;Phase 3   EUCTR2021-001577-24-IT   Belgium;Canada;China;Czech Republic;Czechia;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
Apremilast   
   AMGEN INC.
      2021   Phase 3   EUCTR2019-002788-88-IT   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;
   Amgen Inc.
      2021   Phase 3   EUCTR2019-002788-88-NL   Austria;Belgium;France;Italy;Netherlands;
      2021   Phase 3   EUCTR2019-002788-88-FR   Austria;Belgium;France;Netherlands;
      -   Phase 3   EUCTR2019-002788-88-PL   Austria;Belgium;France;Italy;Netherlands;Poland;
      -   Phase 3   EUCTR2019-002788-88-BE   Austria;Belgium;Netherlands;
      -   Phase 3   EUCTR2019-002788-88-AT   Austria;Belgium;France;Italy;Netherlands;
BMS-188667   
   Bristol-Myers Squibb International Corporation
      2013   Phase 3   EUCTR2012-003195-39-IT   Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States;
      2013   Phase 3   EUCTR2012-003195-39-ES   Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States;
      2013   Phase 3   EUCTR2012-003195-39-DE   Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States;
      2013   Phase 3   EUCTR2012-003195-39-BE   Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States;
      -   Phase 3   EUCTR2012-003195-39-FR   Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States;
      -   -   EUCTR2016-000940-32-Outside-EU/EEA   Japan;
      -   -   EUCTR2012-003195-39-Outside-EU/EEA   Argentina;Belgium;Brazil;France;Germany;Italy;Mexico;Peru;Russian Federation;South Africa;Spain;United States;
Baricitinib   
   Eli Lilly and Company
      2020   Phase 3   NCT04088396   Argentina;Austria;Belgium;Brazil;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
      2019   Phase 3   NCT04088409   France;Germany;Italy;Spain;United Kingdom;
      2019   Phase 3   NCT03773965   Argentina;Australia;Austria;Belgium;Brazil;China;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
      2018   Phase 3   NCT03773978   Argentina;Australia;Austria;Belgium;Brazil;China;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
Biological DMARDs   
   Hoffmann-La Roche
      2000   -   NCT02784808   -
Biosimilar Etanercept   
   FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO
      2021   Phase 4   EUCTR2021-004031-86-IT   Italy;
Biosimilar adalimumab   
   FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO
      2021   Phase 4   EUCTR2021-004031-86-IT   Italy;
Blood sample   
   University Hospital, Montpellier
      2014   -   NCT02067962   -
Bof-, Mazelen-, Rubellavaccin, poeder voor injectievloeistof   
   University Medical Center Utrecht
      2008   -   EUCTR2007-001861-14-NL   Netherlands;
CCP-690-550-10   
   PFIZER INC
      2020   Phase 3   EUCTR2017-002018-29-IT   Argentina;Belgium;Brazil;Canada;Chile;China;Germany;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
CNTO 148 (Golimumab)   
   Janssen Research & Development, LLC
      2010   Phase 3   NCT01230827   Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Poland;Russian Federation;United States;
CNTO148   
   Janssen Biologics B.V.
      2011   Phase 3   EUCTR2009-015019-42-BE   Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Poland;Russian Federation;Serbia;United States;
      2011   -   EUCTR2009-015019-42-DE   Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Peru;Poland;Russian Federation;United States;
      2010   -   EUCTR2009-015019-42-LT   Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Poland;Russian Federation;Serbia;United States;
      2010   -   EUCTR2009-015019-42-FI   Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Poland;Russian Federation;Serbia;United States;
      2010   -   EUCTR2009-015019-42-AT   Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Poland;Russian Federation;Serbia;United States;
      -   -   EUCTR2009-015019-42-Outside-EU/EEA   Argentina;Brazil;Canada;Mexico;Peru;Russian Federation;United States;
COSENTYX - 150 MG - SOLUZIONE INIETTABILE IN SIRINGA PRERIEMPITA -USO SOTTOCUTANEO - SIRINGA (VETRO) 1 ML (150MG/ML)- 1 SIRINGA PRERIEMPITA   
   NOVARTIS PHARMA AG
      -   Phase 3   EUCTR2016-003761-26-IT   Belgium;Germany;Italy;Netherlands;Poland;Spain;Turkey;United Kingdom;United States;
COSENTYX - 150 MG - SOLUZIONE INIETTABILE IN SIRINGA PRERIEMPITA -USO SOTTOCUTANEO - SIRINGA (VETRO) 1 ML (150MG/ML)- 2 SIRINGHE PRERIEMPITE   
   NOVARTIS PHARMA AG
      2019   Phase 3   EUCTR2018-002521-30-IT   Belgium;Germany;Italy;Poland;Russian Federation;South Africa;Spain;Turkey;United States;
CP-690, 550-10   
   PFIZER INC
      2020   Phase 3   EUCTR2017-002018-29-IT   Argentina;Belgium;Brazil;Canada;Chile;China;Germany;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
CP-690,550   
   PFIZER INC.
      2013   -   EUCTR2011-004915-22-IT   Argentina;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;
   Pfizer
      2013   Phase 1   NCT01513902   Germany;Hungary;Poland;Slovakia;United States;
CP-690,550 (tofacitinib)   
   Pfizer
      2016   Phase 3   NCT02592434   Argentina;Australia;Belgium;Brazil;Canada;Chile;Germany;Israel;Mexico;Poland;Russian Federation;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
CP-690,550-10   
   PFIZER INC.
      2012   -   EUCTR2011-004914-40-IT   Argentina;Hungary;Italy;Mexico;Poland;Russian Federation;
   Pfizer Inc
      2012   Phase 2;Phase 3   EUCTR2011-004915-22-SK   Argentina;Australia;Belgium;Brazil;Canada;China;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
   Pfizer Inc, 235 East 42nd Street, New York, NY 10017
      2012   Phase 1   EUCTR2011-004914-40-HU   Argentina;Czech Republic;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;Serbia;Slovakia;
      2012   -   EUCTR2011-004914-40-SK   Argentina;Czech Republic;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;Serbia;Slovakia;
      2012   -   EUCTR2011-004914-40-PL   Argentina;Czech Republic;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;Serbia;Slovakia;
   Pfizer Inc, 235 East 42nd Street, New York, New York 10017
      2019   Phase 3   EUCTR2015-001438-46-PL   Argentina;Australia;Belgium;Brazil;Canada;Chile;Germany;Israel;Mexico;Poland;Russian Federation;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2015-001438-46-ES   Argentina;Australia;Belgium;Brazil;Canada;Chile;Germany;Israel;Mexico;Poland;Russian Federation;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2015-001438-46-DE   Argentina;Australia;Belgium;Brazil;Canada;Chile;Germany;Israel;Mexico;Poland;Russian Federation;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2015-001438-46-BE   Argentina;Australia;Belgium;Brazil;Canada;Chile;Germany;Israel;Mexico;Poland;Russian Federation;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 2;Phase 3   EUCTR2011-004915-22-BE   Argentina;Australia;Belgium;Brazil;Canada;China;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2012   Phase 2;Phase 3   EUCTR2011-004915-22-PL   Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2012   Phase 2;Phase 3   EUCTR2011-004915-22-DE   Argentina;Australia;Belgium;Brazil;Canada;Chile;Germany;Hungary;Israel;Italy;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2012   -   EUCTR2011-004915-22-HU   Czech Republic;Germany;Hungary;Italy;Poland;Russian Federation;Serbia;Slovakia;
      -   Phase 2;Phase 3   EUCTR2011-004915-22-SE   Argentina;Australia;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      -   Phase 2;Phase 3   EUCTR2011-004915-22-NL   Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Costa Rica;Germany;Hungary;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Turkey;Ukraine;United Kingdom;United States;
   Pfizer Inc.
      2020   Phase 3   EUCTR2017-002018-29-SK   Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 3   EUCTR2015-001438-46-GB   Argentina;Australia;Belgium;Brazil;Canada;Chile;Germany;Israel;Mexico;Poland;Russian Federation;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
      2018   Phase 2;Phase 3   EUCTR2011-004915-22-GB   Argentina;Australia;Belgium;Brazil;Canada;Chile;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
   Pfizer Inc. 235 East 42nd Street, New York, New York 10017
      2022   Phase 3   EUCTR2017-002018-29-HU   Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2017-002018-29-NL   Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2017-002018-29-DE   Argentina;Belgium;Brazil;Canada;Chile;China;Eritrea;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2017-002018-29-PL   Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      -   Phase 3   EUCTR2017-002018-29-SE   Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      -   Phase 3   EUCTR2017-002018-29-BE   Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
CP-690-550-10 (DMID D1600180)   
   Pfizer Inc
      2012   Phase 2;Phase 3   EUCTR2011-004915-22-SK   Argentina;Australia;Belgium;Brazil;Canada;China;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
   Pfizer Inc, 235 East 42nd Street, New York, New York 10017
      2018   Phase 2;Phase 3   EUCTR2011-004915-22-BE   Argentina;Australia;Belgium;Brazil;Canada;China;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      -   Phase 2;Phase 3   EUCTR2011-004915-22-SE   Argentina;Australia;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
   Pfizer Inc.
      2020   Phase 3   EUCTR2017-002018-29-SK   Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
   Pfizer Inc. 235 East 42nd Street, New York, New York 10017
      2022   Phase 3   EUCTR2017-002018-29-HU   Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2017-002018-29-NL   Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2017-002018-29-DE   Argentina;Belgium;Brazil;Canada;Chile;China;Eritrea;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2017-002018-29-PL   Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      -   Phase 3   EUCTR2017-002018-29-SE   Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      -   Phase 3   EUCTR2017-002018-29-BE   Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
CSs   
   Hoffmann-La Roche
      2018   Phase 4   NCT03301883   China;
Canakinumab   
   NOVARTIS FARMA
      2009   -   EUCTR2008-008008-42-IT   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-005479-82-IT   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-005476-27-IT   Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
   Novartis Farmacéutica S.A.
      2009   Phase 3   EUCTR2008-005476-27-ES   Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Norway;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-008008-42-ES   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-005479-82-ES   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
   Novartis Pharma K.K.
      2015   Phase 3   JPRN-JapicCTI-152865   -
   Novartis Pharma Services AG
      2010   -   EUCTR2008-008008-42-GR   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2008-005479-82-GR   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2008-005476-27-GR   Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2008-005476-27-GB   Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
      2009   Phase 3   EUCTR2008-005479-82-FR   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Norway;Spain;Sweden;United Kingdom;
      2009   Phase 3   EUCTR2008-005479-82-BE   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
      2009   Phase 3   EUCTR2008-005476-27-FR   Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Norway;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-008008-42-SE   Argentina;Austria;Belgium;Brazil;Canada;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Peru;Russian Federation;Spain;Swaziland;Sweden;Turkey;United Kingdom;United States;
      2009   -   EUCTR2008-008008-42-GB   Argentina;Austria;Belgium;Brazil;Canada;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Norway;Peru;Poland;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2009   -   EUCTR2008-008008-42-FR   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-008008-42-DK   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-008008-42-DE   Argentina;Austria;Belgium;Brazil;Canada;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Norway;Peru;Poland;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2009   -   EUCTR2008-005479-82-SE   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-005479-82-HU   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-005479-82-GB   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-005479-82-DK   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-005479-82-DE   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-005479-82-AT   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-005476-27-SE   Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-005476-27-HU   Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-005476-27-DK   Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-005476-27-DE   Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-005476-27-BE   Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
      -   Phase 3   EUCTR2008-008008-42-NO   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom;
      -   Phase 3   EUCTR2008-005479-82-NO   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Norway;Spain;Sweden;United Kingdom;
      -   Phase 3   EUCTR2008-005476-27-NO   Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Norway;Spain;Sweden;United Kingdom;
   Novartis Pharmaceuticals
      2015   Phase 3   NCT02396212   Japan;
      2014   Phase 3   NCT02334748   France;
      2013   Phase 3   NCT01676948   Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2009   Phase 3   NCT00891046   Argentina;Austria;Belgium;Brazil;Canada;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Norway;Peru;Poland;Russian Federation;South Africa;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2009   Phase 3   NCT00889863   Argentina;Belgium;Brazil;Canada;France;Germany;Hungary;Israel;Italy;Netherlands;Norway;Peru;Poland;South Africa;Spain;Sweden;Switzerland;Turkey;United States;
      2009   Phase 3   NCT00886769   Argentina;Belgium;Brazil;Canada;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Norway;Peru;Poland;South Africa;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
Celebrex   
   Pfizer Inc
      -   -   EUCTR2014-003737-26-Outside-EU/EEA   Chile;Costa Rica;Peru;Philippines;Russian Federation;Serbia;South Africa;Ukraine;United States;
Celecoxib   
   Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
      2009   Phase 4   NCT00807846   Chile;Costa Rica;Peru;Philippines;Russian Federation;Serbia;South Africa;Switzerland;Ukraine;United States;
      2009   -   NCT00688545   United States;
Certolizumab Pegol (CZP)   
   UCB BIOSCIENCES GmbH
      2012   Phase 3   NCT01550003   Argentina;Brazil;Canada;Chile;Mexico;Russian Federation;United States;
Cervarix suspensie voor injectie   
   University Medical Center Utrecht
      2009   -   EUCTR2008-008169-36-NL   Netherlands;
Collection of samples   
   Institut National de la Santé Et de la Recherche Médicale, France
      2021   -   NCT04902807   -
Combination of DMARDs   
   Helsinki University Central Hospital
      2003   Phase 3   NCT01015547   Finland;
Corticosteroids   
   Hoffmann-La Roche
      2008   Phase 3   NCT00642460   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;France;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
Cyclosporine A   
   St. Franziskus Hospital
      1991   -   NCT00404482   Germany;
Daclizumab   
   National Eye Institute (NEI)
      2005   Phase 2   NCT00130637   United States;
Dexmedetomidine   
   University of Oulu
      2017   Phase 4   NCT03069638   Finland;
Diethyl-[6-(4-hydroxycarbamoyl- phenyl carbamoyloxymethyl)-naphthalen-2-yl methyl]-ammonium chloride   
   Italfarmaco S.p.A.
      2011   -   EUCTR2011-003341-18-CZ   Czech Republic;
Double-Blind Adalimumab   
   Abbott
      2002   Phase 3   NCT00048542   Belgium;Czech Republic;France;Germany;Italy;Slovakia;Spain;United States;
ENBREL 25 mg/ml polvo y disolvente para solución inyectable para uso pediátrico   
   PFIZER, S.L.U.
      2011   -   EUCTR2010-023802-10-ES   Australia;Belgium;Colombia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Slovakia;Slovenia;Spain;
   Pfizer Inc., 235 East 42nd Street, New York, NY 10017, United States
      2012   Phase 3   EUCTR2010-023802-10-NL   Australia;Belgium;Colombia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Slovakia;Slovenia;Spain;
ENBREL 50 mg solución inyectable en jeringas precargadas   
   PFIZER, S.L.U.
      2011   -   EUCTR2010-023802-10-ES   Australia;Belgium;Colombia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Slovakia;Slovenia;Spain;
   Pfizer Inc., 235 East 42nd Street, New York, NY 10017, United States
      2012   Phase 3   EUCTR2010-023802-10-NL   Australia;Belgium;Colombia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Slovakia;Slovenia;Spain;
ENBREL*BB SC 4FL 25MG 1ML+4SIR   
   Wyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical Research and Development
      2010   -   EUCTR2009-012520-84-IT   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Slovenia;Spain;Sweden;
EU/1/03/256/001   
   University Medical Center Utrecht
      2014   -   EUCTR2013-003956-18-NL   Canada;Germany;Latvia;Netherlands;United States;
EU/1/07/389/001   
   University Medical Center Utrecht
      2014   -   EUCTR2013-003956-18-NL   Canada;Germany;Latvia;Netherlands;United States;
EU/1/99/126/001   
   University Medical Center Utrecht
      2014   -   EUCTR2013-003956-18-NL   Canada;Germany;Latvia;Netherlands;United States;
EX VIVO CULTURED HUMAN MESENCHYMAL STEM CELLS   
   University Medical Center Utrecht
      2014   -   EUCTR2012-002067-10-NL   Netherlands;
Emapalumab   
   Novimmune SA
      2017   Phase 2   EUCTR2016-004223-23-ES   France;Germany;Italy;Netherlands;Spain;United Kingdom;
   Swedish Orphan Biovitrum
      2018   Phase 2   NCT03311854   France;Italy;Netherlands;Spain;United Kingdom;United States;
   Swedish Orphan Biovitrum AG
      -   Phase 2;Phase 3   EUCTR2021-001577-24-IT   Belgium;Canada;China;Czech Republic;Czechia;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
   Swedish Orphan Biovitrum AG (Sobi AG)
      2021   Phase 2;Phase 3   EUCTR2021-001577-24-PL   Belgium;Canada;China;Czechia;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2021   Phase 2;Phase 3   EUCTR2021-001577-24-ES   Belgium;Canada;China;Czechia;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
      -   Phase 2;Phase 3   EUCTR2021-001577-24-SE   Belgium;Canada;China;Czechia;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
      -   Phase 2;Phase 3   EUCTR2021-001577-24-FR   Belgium;Canada;China;Czechia;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
      -   Phase 2;Phase 3   EUCTR2021-001577-24-CZ   Belgium;Canada;China;Czech Republic;Czechia;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
Enbrel   
   IRCCS Istituto Giannina Gaslini
      2019   Phase 3   EUCTR2018-001931-27-IT   Italy;
   PFIZER INC.
      2012   -   EUCTR2010-023802-10-IT   Australia;Belgium;Colombia;Czech Republic;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Netherlands;Russian Federation;Slovakia;Slovenia;Spain;
   University Medical Center Utrecht
      2014   -   EUCTR2013-003956-18-NL   Canada;Germany;Latvia;Netherlands;United States;
   Wyeth Kabushiki Kaisha (Wyeth K.K.)
      -   -   EUCTR2014-004103-73-Outside-EU/EEA   Japan;
   Wyeth Pharmaceuticals Inc, (a Pfizer Company) 500 Arcola Road, Collegeville, PA 19426 USA
      2010   -   EUCTR2009-012520-84-CZ   Belgium;Czech Republic;Denmark;Egypt;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Norway;Poland;Russian Federation;Slovenia;Spain;Sweden;
      2009   Phase 3   EUCTR2009-012520-84-BE   Belgium;Czech Republic;Denmark;Egypt;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Norway;Poland;Russian Federation;Slovakia;Slovenia;Spain;Sweden;
      2009   -   EUCTR2009-012520-84-SI   Belgium;Czech Republic;Denmark;Egypt;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Norway;Poland;Russian Federation;Slovenia;Spain;Sweden;
      2009   -   EUCTR2009-012520-84-LV   Belgium;Czech Republic;Denmark;Egypt;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Norway;Poland;Russian Federation;Slovenia;Spain;Sweden;
      2009   -   EUCTR2009-012520-84-LT   Belgium;Czech Republic;Denmark;Egypt;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Norway;Poland;Russian Federation;Slovenia;Spain;Sweden;
      2009   -   EUCTR2009-012520-84-DE   Belgium;Czech Republic;Denmark;Egypt;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Norway;Poland;Russian Federation;Slovenia;Spain;Sweden;
      -   -   EUCTR2009-012520-84-Outside-EU/EEA   Australia;Colombia;Mexico;Russian Federation;Serbia;
   Wyeth Research Division of Wyeth Pharmaceuticals Inc. A Pfizer Company,Philadelphia,PA-19101,USA
      2009   Phase 3   EUCTR2009-012520-84-SK   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Slovakia;Slovenia;Spain;Sweden;
   Wyeth Research Division of Wyeth Pharmaceuticals Inc., A Pfizer Company, Philadelphia, PA-19101, USA
      2010   -   EUCTR2009-012520-84-DK   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Slovenia;Spain;Sweden;
      2009   -   EUCTR2009-012520-84-SE   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Slovenia;Spain;Sweden;
   Wyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical Research and Development
      2010   Phase 3   EUCTR2009-012520-84-GR   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Slovakia;Slovenia;Spain;Sweden;
      2010   -   EUCTR2009-012520-84-NL   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Slovenia;Spain;Sweden;
      2009   Phase 3   EUCTR2009-012520-84-ES   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Slovakia;Slovenia;Spain;Sweden;
      2009   -   EUCTR2009-012520-84-HU   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Slovenia;Spain;Sweden;
      2009   -   EUCTR2009-012520-84-FR   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Slovenia;Spain;Sweden;
Enbrel (Etanercept)   
   Amgen, Inc. One Amgen Center Drive Thousand Oaks, California 91320
      -   -   EUCTR2012-001171-37-Outside-EU/EEA   Canada;United States;
      -   -   EUCTR2012-001145-40-Outside-EU/EEA   Canada;United States;
Enbrel®   
   Asklepios-Klinik Sankt Augustin
      2007   -   EUCTR2007-000255-34-DE   Germany;
   Pfizer Inc.235 East 42nd Street, New York, NY 10017
      2012   Phase 3   EUCTR2010-023802-10-NO   Australia;Belgium;Colombia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Slovakia;Slovenia;Spain;
      2011   Phase 3   EUCTR2010-023802-10-SK   Australia;Belgium;Colombia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Slovakia;Slovenia;Spain;
      2011   Phase 3   EUCTR2010-023802-10-SI   Australia;Belgium;Colombia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Slovakia;Slovenia;Spain;
      2011   Phase 3   EUCTR2010-023802-10-LV   Australia;Belgium;Colombia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Slovakia;Slovenia;Spain;
      2011   Phase 3   EUCTR2010-023802-10-LT   Australia;Belgium;Colombia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Slovakia;Slovenia;Spain;
      2011   Phase 3   EUCTR2010-023802-10-HU   Australia;Belgium;Colombia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Slovakia;Slovenia;Spain;
      2011   Phase 3   EUCTR2010-023802-10-FR   Australia;Belgium;Colombia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Slovakia;Slovenia;Spain;
      2011   Phase 3   EUCTR2010-023802-10-DE   Australia;Belgium;Colombia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Slovakia;Slovenia;Spain;
      2011   Phase 3   EUCTR2010-023802-10-CZ   Australia;Belgium;Colombia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Slovakia;Slovenia;Spain;
      2011   Phase 3   EUCTR2010-023802-10-BE   Australia;Belgium;Colombia;Czech Republic;Czechia;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Slovakia;Slovenia;Spain;
      -   Phase 3   EUCTR2010-023802-10-PL   Australia;Belgium;Colombia;Czech Republic;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Slovakia;Slovenia;Spain;
      -   -   EUCTR2010-023802-10-Outside-EU/EEA   Australia;Colombia;Mexico;Russian Federation;Serbia;
   Samsung Bioepis Co., Ltd.
      2013   Phase 3   EUCTR2012-005026-30-HU   Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
      2013   -   EUCTR2012-005026-30-PL   Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
      2013   -   EUCTR2012-005026-30-CZ   Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
      2013   -   EUCTR2012-005026-30-BG   Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
Entecavir   
   Seoul National University Hospital
      2012   Phase 3   NCT01694264   Korea, Republic of;
Esomeprazole   
   AstraZeneca
      2011   Phase 1   NCT01358383   United States;
Etanercept   
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2016   Phase 3   EUCTR2016-000312-15-FR   France;
   Assistance Publique - Hôpitaux de Paris
      2017   Phase 3   NCT02840175   France;
   Erasmus Medical Center
      2011   Phase 4   NCT01287715   Netherlands;
   Pfizer
      2011   Phase 3   NCT01421069   Australia;Belgium;Colombia;Czech Republic;Czechia;France;Germany;Hungary;Italy;Latvia;Lithuania;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Slovakia;Slovenia;Spain;
      2009   Phase 3   NCT00962741   Argentina;Australia;Belgium;Brazil;Colombia;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Mexico;Netherlands;Norway;Poland;Russian Federation;Serbia;Slovakia;Slovenia;Spain;Sweden;Taiwan;
   Wyeth Pharmaceuticals Inc, (a Pfizer Company) 500 Arcola Road, Collegeville, PA 19426 USA
      2010   -   EUCTR2009-012520-84-CZ   Belgium;Czech Republic;Denmark;Egypt;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Norway;Poland;Russian Federation;Slovenia;Spain;Sweden;
      2009   Phase 3   EUCTR2009-012520-84-BE   Belgium;Czech Republic;Denmark;Egypt;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Norway;Poland;Russian Federation;Slovakia;Slovenia;Spain;Sweden;
      2009   -   EUCTR2009-012520-84-SI   Belgium;Czech Republic;Denmark;Egypt;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Norway;Poland;Russian Federation;Slovenia;Spain;Sweden;
      2009   -   EUCTR2009-012520-84-LV   Belgium;Czech Republic;Denmark;Egypt;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Norway;Poland;Russian Federation;Slovenia;Spain;Sweden;
      2009   -   EUCTR2009-012520-84-LT   Belgium;Czech Republic;Denmark;Egypt;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Norway;Poland;Russian Federation;Slovenia;Spain;Sweden;
      2009   -   EUCTR2009-012520-84-DE   Belgium;Czech Republic;Denmark;Egypt;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Norway;Poland;Russian Federation;Slovenia;Spain;Sweden;
      -   -   EUCTR2009-012520-84-Outside-EU/EEA   Australia;Colombia;Mexico;Russian Federation;Serbia;
   Wyeth Research Division of Wyeth Pharmaceuticals Inc. A Pfizer Company,Philadelphia,PA-19101,USA
      2009   Phase 3   EUCTR2009-012520-84-SK   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Slovakia;Slovenia;Spain;Sweden;
   Wyeth Research Division of Wyeth Pharmaceuticals Inc., A Pfizer Company, Philadelphia, PA-19101, USA
      2010   -   EUCTR2009-012520-84-DK   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Slovenia;Spain;Sweden;
      2009   -   EUCTR2009-012520-84-SE   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Slovenia;Spain;Sweden;
   Wyeth Research Division of Wyeth Pharmaceuticals Inc., Clinical Research and Development
      2010   Phase 3   EUCTR2009-012520-84-GR   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Slovakia;Slovenia;Spain;Sweden;
      2010   -   EUCTR2009-012520-84-NL   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Slovenia;Spain;Sweden;
      2010   -   EUCTR2009-012520-84-IT   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Slovenia;Spain;Sweden;
      2009   Phase 3   EUCTR2009-012520-84-ES   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Slovakia;Slovenia;Spain;Sweden;
      2009   -   EUCTR2009-012520-84-HU   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Slovenia;Spain;Sweden;
      2009   -   EUCTR2009-012520-84-FR   Belgium;Czech Republic;Denmark;France;Germany;Greece;Hungary;Italy;Latvia;Lithuania;Netherlands;Slovenia;Spain;Sweden;
   Wyeth is now a wholly owned subsidiary of Pfizer
      2003   -   NCT00195377   Spain;
Etanercept (genetical recombination)   
   Pfizer
      2009   -   NCT01145352   Japan;
Etanercept Optimal dosing   
   Duke University
      2023   Phase 1   NCT04585711   United States;
Etanercept biosimilare   
   FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO
      2021   Phase 4   EUCTR2021-004031-86-IT   Italy;
Folic/folinic acid   
   University of British Columbia
      2019   -   NCT04169828   Canada;
Fully human anti-interferon gamma monoclonal antibody   
   Novimmune SA
      -   Phase 2   EUCTR2016-004223-23-FR   Canada;France;Italy;Netherlands;Spain;United Kingdom;United States;
Genakumab   
   GeneScience Pharmaceuticals Co., Ltd.
      2019   Phase 1   NCT04337437   China;
Genicular nerve block   
   Sohag University
      2020   Phase 4   NCT04687930   Egypt;
Genotropin   
   Ludwig-Maximilians - University of Munich
      1996   Phase 3   NCT00420251   Germany;
   Pfizer Inc
      -   -   EUCTR2014-004105-32-Outside-EU/EEA   France;
   Pharmacia & Upjohn S.A.
      -   -   EUCTR2014-004104-30-Outside-EU/EEA   France;
Givinostat   
   ITALFARMACO
      2010   -   EUCTR2010-019094-15-IT   Czech Republic;Italy;Slovenia;Spain;
   Italfarmaco
      2011   -   NCT01557452   Czech Republic;
      2010   Phase 2   NCT01261624   Belgium;Czech Republic;Italy;Romania;Serbia;Slovenia;Spain;
Givinostat (hydrochloride-monohydrate)   
   Italfarmaco S.p.A.
      2011   -   EUCTR2011-003341-18-CZ   Czech Republic;
      2010   Phase 2   EUCTR2010-019094-15-BE   Belgium;Czech Republic;Italy;Slovenia;Spain;
      2010   -   EUCTR2010-019094-15-SI   Czech Republic;Italy;Slovenia;Spain;
      2010   -   EUCTR2010-019094-15-ES   Czech Republic;Italy;Slovenia;Spain;
      2010   -   EUCTR2010-019094-15-CZ   Czech Republic;Italy;Slovenia;Spain;
Golimumab   
   Janssen Research & Development, LLC
      2014   Phase 3   NCT02277444   Argentina;Brazil;Canada;Chile;Israel;Mexico;Puerto Rico;Russian Federation;South Africa;United States;
   Medical University of Graz
      2010   -   NCT04200833   -
Golimumab Liquid in prefilled syringe   
   Janssen Biologics B.V.
      2011   Phase 3   EUCTR2009-015019-42-BE   Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Poland;Russian Federation;Serbia;United States;
      2011   -   EUCTR2009-015019-42-DE   Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Peru;Poland;Russian Federation;United States;
      2010   -   EUCTR2009-015019-42-LT   Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Poland;Russian Federation;Serbia;United States;
      2010   -   EUCTR2009-015019-42-FI   Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Poland;Russian Federation;Serbia;United States;
      2010   -   EUCTR2009-015019-42-AT   Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Poland;Russian Federation;Serbia;United States;
      -   -   EUCTR2009-015019-42-Outside-EU/EEA   Argentina;Brazil;Canada;Mexico;Peru;Russian Federation;United States;
HUMIRA   
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2016   Phase 3   EUCTR2016-000312-15-FR   France;
Heparin   
   Shanghai Children's Medical Center
      2015   -   ChiCTR-OOC-15006228   China;
Human anti-TNF-alpha monoclonal antibody   
   Janssen Biologics B.V.
      2011   Phase 3   EUCTR2009-015019-42-BE   Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Poland;Russian Federation;Serbia;United States;
      2011   -   EUCTR2009-015019-42-DE   Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Peru;Poland;Russian Federation;United States;
      2010   -   EUCTR2009-015019-42-LT   Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Poland;Russian Federation;Serbia;United States;
      2010   -   EUCTR2009-015019-42-FI   Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Poland;Russian Federation;Serbia;United States;
      2010   -   EUCTR2009-015019-42-AT   Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Poland;Russian Federation;Serbia;United States;
      -   -   EUCTR2009-015019-42-Outside-EU/EEA   Argentina;Brazil;Canada;Mexico;Peru;Russian Federation;United States;
Humira   
   AbbVie Deutschland GmbH & Co. KG
      2010   -   EUCTR2009-013091-40-SE   Czech Republic;France;Germany;Sweden;
      2010   -   EUCTR2009-013091-40-CZ   Czech Republic;France;Germany;Sweden;
   Abbott GmbH & Co. KG
      2010   Phase 3   EUCTR2009-013091-40-SK   Czech Republic;Denmark;France;Germany;Slovakia;Sweden;
      2010   Phase 3   EUCTR2009-013091-40-FR   Czech Republic;Denmark;France;Germany;Slovakia;Sweden;
      2010   Phase 3   EUCTR2009-013091-40-DK   Czech Republic;Denmark;France;Germany;Sweden;
      2010   -   EUCTR2009-013091-40-DE   Czech Republic;France;Germany;Sweden;
      -   -   EUCTR2009-013091-40-Outside-EU/EEA   -
   ELI LILLY & COMPANY, LILLY CORPORATE CENTER
      2020   Phase 3   EUCTR2018-000681-10-IT   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
      2019   Phase 3   EUCTR2019-000119-10-IT   European Union;France;Germany;Italy;United Kingdom;
   Eli Lilly and Company
      2021   Phase 3   EUCTR2018-000681-10-CZ   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
      2020   Phase 3   EUCTR2019-000119-10-DE   France;Germany;Italy;Spain;United Kingdom;
      2020   Phase 3   EUCTR2018-000681-10-GB   Belgium;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
      2020   Phase 3   EUCTR2018-000681-10-DK   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
      2020   Phase 3   EUCTR2018-000681-10-DE   Belgium;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
      2019   Phase 3   EUCTR2019-000119-10-GB   France;Germany;United Kingdom;
      2019   Phase 3   EUCTR2019-000119-10-FR   France;Germany;United Kingdom;
      -   Phase 3   EUCTR2018-000681-10-NL   Belgium;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
      -   Phase 3   EUCTR2018-000681-10-FR   Belgium;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
      -   Phase 3   EUCTR2018-000681-10-BE   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
   F.I. Proctor Foundation, University of California San Francisco
      2019   Phase 4   EUCTR2019-000412-29-GB   Australia;United Kingdom;United States;
   FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO
      2021   Phase 4   EUCTR2021-004031-86-IT   Italy;
   University Medical Center Utrecht
      2014   -   EUCTR2013-003956-18-NL   Canada;Germany;Latvia;Netherlands;United States;
Humira®   
   Samsung Bioepis Co., Ltd.
      2014   Phase 3   EUCTR2013-005013-13-BG   Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom;
      2014   -   EUCTR2013-005013-13-PL   Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom;
      2014   -   EUCTR2013-005013-13-LT   Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom;
      2014   -   EUCTR2013-005013-13-CZ   Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom;
IL-2   
   The First Hospital of Jilin University
      2020   -   NCT04397107   China;
IL-6 receptor inhibitor, recombinant humanized monoclonal antibody   
   F. Hoffmann-La Roche Ltd
      2015   Phase 1   EUCTR2015-000435-33-PL   Belgium;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom;
      2015   Phase 1   EUCTR2015-000435-33-HU   Belgium;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom;
      2015   Phase 1   EUCTR2015-000435-33-GB   Belgium;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom;
      2015   Phase 1   EUCTR2015-000435-33-DE   Belgium;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom;
      2015   Phase 1   EUCTR2015-000435-33-BE   Belgium;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom;
      2009   Phase 3   EUCTR2009-011593-15-GB   Argentina;Australia;Belgium;Brazil;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
      2009   Phase 3   EUCTR2009-011593-15-BE   Argentina;Australia;Belgium;Brazil;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
      -   Phase 1   EUCTR2015-000435-33-FR   Argentina;Belgium;Canada;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom;United States;
   F. Hoffmann-La Roche Ltd.
      2012   Phase 4   EUCTR2012-000444-10-SE   Australia;Canada;Germany;Israel;Italy;Mexico;Norway;Russian Federation;Spain;Sweden;United Kingdom;
      2012   Phase 4   EUCTR2012-000444-10-GB   Australia;Canada;Germany;Israel;Italy;Mexico;Norway;Russian Federation;Spain;Sweden;United Kingdom;
      2012   Phase 4   EUCTR2012-000444-10-ES   Australia;Canada;Germany;Italy;Mexico;Norway;Spain;Sweden;United Kingdom;
      2012   Phase 4   EUCTR2012-000444-10-DE   Australia;Canada;Germany;Israel;Italy;Mexico;Norway;Russian Federation;Spain;Sweden;United Kingdom;
      2008   Phase 3   EUCTR2007-000872-18-GB   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
      2008   -   EUCTR2007-000872-18-DE   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
      2008   -   EUCTR2007-000872-18-CZ   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
      2008   -   EUCTR2007-000872-18-BE   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
      -   Phase 4   EUCTR2012-000444-10-NO   Australia;Canada;Germany;Italy;Mexico;Norway;Spain;Sweden;United Kingdom;
   Roche Farma S.A en nombre de F. Hoffmann-La Roche Ltd
      2015   Phase 1   EUCTR2015-000435-33-ES   Belgium;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom;
ITF2357   
   ITALFARMACO
      2006   -   EUCTR2006-000089-35-IT   Italy;
   Italfarmaco
      2006   Phase 2   NCT00570661   Former Serbia and Montenegro;Serbia;
   Italfarmaco S.p.A.
      2011   -   EUCTR2011-003341-18-CZ   Czech Republic;
      2010   Phase 2   EUCTR2010-019094-15-BE   Belgium;Czech Republic;Italy;Slovenia;Spain;
      2010   -   EUCTR2010-019094-15-SI   Czech Republic;Italy;Slovenia;Spain;
      2010   -   EUCTR2010-019094-15-ES   Czech Republic;Italy;Slovenia;Spain;
      2010   -   EUCTR2010-019094-15-CZ   Czech Republic;Italy;Slovenia;Spain;
Ilaris   
   Asklepios Klink Sankt Augustin
      2020   Phase 4   EUCTR2018-004284-30-DE   Germany;
   Novartis Farmacéutica, S.A.
      2014   Phase 3;Phase 4   EUCTR2013-004867-29-ES   Argentina;Austria;Belgium;Brazil;Canada;France;Germany;Hong Kong;Hungary;Israel;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;Sweden;Turkey;United States;
   Novartis Pharma Services AG
      2009   -   EUCTR2008-008008-42-BE   Argentina;Austria;Belgium;Brazil;Canada;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Peru;Poland;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
In double-blind phase: treatment with tofacitinib   
   Pfizer
      2018   Phase 3   NCT03000439   Argentina;Belgium;Brazil;Canada;Chile;China;Costa Rica;Germany;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Turkey;Ukraine;United Kingdom;United States;
In open-label phase: treatment with tofacitinib   
   Pfizer
      2018   Phase 3   NCT03000439   Argentina;Belgium;Brazil;Canada;Chile;China;Costa Rica;Germany;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Turkey;Ukraine;United Kingdom;United States;
Infliximab plus methotrexate   
   Helsinki University Central Hospital
      2003   Phase 3   NCT01015547   Finland;
Influenza vaccine, Immune function   
   University of Pecs
      2018   Early Phase 1   NCT03833271   Hungary;
Intra-articular steroid injection   
   Sohag University
      2020   Phase 4   NCT04687930   Egypt;
Ixekizumab   
   ELI LILLY & COMPANY, LILLY CORPORATE CENTER
      2020   Phase 3   EUCTR2018-000681-10-IT   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
   Eli Lilly and Company
      2021   Phase 3   NCT04527380   Argentina;Belgium;Czechia;Denmark;France;Germany;Italy;Mexico;Netherlands;Spain;Switzerland;United Kingdom;
KINERET*SC 7SIR 100MG 0,67ML   
   ISTITUTO GIANNINA GASLINI
      2005   -   EUCTR2005-004008-36-IT   Italy;
Kineret® or anakinra   
   University Medical Center Utrecht
      2016   Phase 4   EUCTR2015-004393-16-NL   Netherlands;
L01BA01   
   ISTITUTO GIANNINA GASLINI-PRINTO
      2005   -   EUCTR2005-001086-34-DK   Denmark;Italy;Spain;
   Istituto Giannina Gaslini-PRINTO
      2005   -   EUCTR2005-001086-34-ES   Denmark;Italy;Spain;
L04AB04   
   ELI LILLY & COMPANY, LILLY CORPORATE CENTER
      2020   Phase 3   EUCTR2018-000681-10-IT   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
      2019   Phase 3   EUCTR2019-000119-10-IT   European Union;France;Germany;Italy;United Kingdom;
   Eli Lilly and Company
      2020   Phase 3   EUCTR2019-000119-10-DE   France;Germany;Italy;Spain;United Kingdom;
      2019   Phase 3   EUCTR2019-000119-10-GB   France;Germany;United Kingdom;
      2019   Phase 3   EUCTR2019-000119-10-FR   France;Germany;United Kingdom;
LY2439821   
   Eli Lilly and Company
      2021   Phase 3   EUCTR2018-000681-10-CZ   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
      2020   Phase 3   EUCTR2018-000681-10-GB   Belgium;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
      2020   Phase 3   EUCTR2018-000681-10-DK   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
      2020   Phase 3   EUCTR2018-000681-10-DE   Belgium;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
      -   Phase 3   EUCTR2018-000681-10-NL   Belgium;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
      -   Phase 3   EUCTR2018-000681-10-FR   Belgium;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
      -   Phase 3   EUCTR2018-000681-10-BE   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
LY3009104   
   ELI LILLY & COMPANY, LILLY CORPORATE CENTER
      2019   Phase 3   EUCTR2019-000119-10-IT   European Union;France;Germany;Italy;United Kingdom;
      2019   Phase 3   EUCTR2017-004518-24-IT   Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
      2019   Phase 3   EUCTR2017-004495-60-IT   Argentina;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
      2019   Phase 3   EUCTR2017-004471-31-IT   Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
   Eli Lilly and Company
      2020   Phase 3   EUCTR2019-000119-10-DE   France;Germany;Italy;Spain;United Kingdom;
      2019   Phase 3   EUCTR2019-000119-10-GB   France;Germany;United Kingdom;
      2019   Phase 3   EUCTR2019-000119-10-FR   France;Germany;United Kingdom;
      2019   Phase 3   EUCTR2017-004518-24-PL   Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
      2019   Phase 3   EUCTR2017-004518-24-GB   Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
      2019   Phase 3   EUCTR2017-004518-24-FR   Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
      2019   Phase 3   EUCTR2017-004518-24-DK   Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
      2019   Phase 3   EUCTR2017-004518-24-DE   Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
      2019   Phase 3   EUCTR2017-004518-24-CZ   Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
      2019   Phase 3   EUCTR2017-004518-24-BE   Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
      2019   Phase 3   EUCTR2017-004518-24-AT   Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
      2019   Phase 3   EUCTR2017-004471-31-PL   Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
      2019   Phase 3   EUCTR2017-004471-31-GB   Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
      2019   Phase 3   EUCTR2017-004471-31-FR   Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
      2019   Phase 3   EUCTR2017-004471-31-DK   Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
      2019   Phase 3   EUCTR2017-004471-31-DE   Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
      2019   Phase 3   EUCTR2017-004471-31-CZ   Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
      2019   Phase 3   EUCTR2017-004471-31-BE   Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
      -   Phase 3   EUCTR2017-004471-31-AT   Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
   Lilly S.A.
      2019   Phase 3   EUCTR2017-004518-24-ES   Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
      2019   Phase 3   EUCTR2017-004471-31-ES   Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
Lederspan   
   Oslo University Hospital
      2020   Phase 4   EUCTR2019-000889-38-NO   Norway;
Leflunomide   
   Mashhad University of Medical Sciences
      2013   Phase 4   NCT02024334   Iran, Islamic Republic of;
Lidocaine   
   Sohag University
      2021   Phase 3   NCT04775225   Egypt;
METHOTREXATE DISODIUM   
   University of Munster
      2008   Phase 4   EUCTR2006-006812-31-DE   Germany;Netherlands;
   university medical centre utrecht
      2007   Phase 4   EUCTR2006-006812-31-NL   Germany;Netherlands;
METHOTREXATE*25CPR 2,   
   ISTITUTO GIANNINA GASLINI
      2008   -   EUCTR2008-006741-70-IT   Italy;
MRA   
   F. Hoffmann-La Roche Limited
      2008   -   EUCTR2007-000872-18-SK   Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2007-000872-18-DK   Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
MRA (Actemra)   
   F. Hoffmann-La Roche Ltd.
      2008   Phase 3   EUCTR2007-000872-18-GR   Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Norway;Slovakia;Spain;Sweden;United Kingdom;
MRA (tocilizumab)   
   Chugai Pharmaceutical Co., Ltd.
      -   Phase 3   JPRN-JapicCTI-050017   -
MRA(Tocilizumab)   
   Chugai Pharmaceutical
      2005   Phase 3   NCT00144625   -
      2004   Phase 3   NCT00144664   -
      2004   Phase 3   NCT00144612   -
      2004   Phase 3   NCT00144599   -
MRA, Actemra   
   F. Hoffmann-La Roche Limited
      2008   -   EUCTR2007-000872-18-SE   Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2007-000872-18-NL   Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
MSB11022   
   Fresenius Kabi SwissBioSim GmbH
      2019   Phase 1   NCT04018599   United States;
MTX   
   Hoffmann-La Roche
      2018   Phase 4   NCT03301883   China;
Measles, Mumps, Rubella vaccination   
   N.M. Wulffraat
      2008   Phase 4   NCT00731965   Netherlands;
Methotrexate   
   AbbVie
      2008   -   NCT00783510   Australia;Austria;Czech Republic;Czechia;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Norway;Portugal;Puerto Rico;Slovakia;Spain;Sweden;United States;
   Hoffmann-La Roche
      2008   Phase 3   NCT00642460   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;France;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
   ISTITUTO GIANNINA GASLINI
      2005   -   EUCTR2005-001086-34-IT   Denmark;Italy;Spain;
   ISTITUTO GIANNINA GASLINI-PRINTO
      2005   -   EUCTR2005-001086-34-DK   Denmark;Italy;Spain;
   Institute of Child Health
      2006   -   NCT00415935   United Kingdom;
   Istituto Giannina Gaslini-PRINTO
      2005   -   EUCTR2005-001086-34-ES   Denmark;Italy;Spain;
   Janssen Research & Development, LLC
      2014   Phase 3   NCT02277444   Argentina;Brazil;Canada;Chile;Israel;Mexico;Puerto Rico;Russian Federation;South Africa;United States;
      2010   Phase 3   NCT01230827   Argentina;Austria;Belgium;Brazil;Canada;Finland;Germany;Lithuania;Mexico;Netherlands;Poland;Russian Federation;United States;
   Leiden University
      -   Phase 4   EUCTR2018-001571-21-NL   Netherlands;
   University of British Columbia
      2019   -   NCT04169828   Canada;
Methotrexate - etanercept - prednisolone arm   
   Seattle Children's Hospital
      2007   Phase 4   NCT00443430   United States;
Methotrexate alone   
   Helsinki University Central Hospital
      2003   Phase 3   NCT01015547   Finland;
Methotrexate prefilled pen   
   medac GmbH
      2014   Early Phase 1   NCT02052167   United States;
Metoject   
   University of Munster
      2008   Phase 4   EUCTR2006-006812-31-DE   Germany;Netherlands;
   university medical centre utrecht
      2007   Phase 4   EUCTR2006-006812-31-NL   Germany;Netherlands;
Metotrexato   
   Istituto Giannina Gaslini-PRINTO
      2005   -   EUCTR2005-001086-34-ES   Denmark;Italy;Spain;
NAPROXEN SODIUM   
   Pfizer Inc
      -   -   EUCTR2014-003737-26-Outside-EU/EEA   Chile;Costa Rica;Peru;Philippines;Russian Federation;Serbia;South Africa;Ukraine;United States;
NI-0501   
   Novimmune SA
      2018   Phase 2   EUCTR2016-004223-23-NL   Canada;France;Germany;Italy;Netherlands;Spain;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-004223-23-IT   France;Germany;Italy;Netherlands;Spain;United Kingdom;
      2017   Phase 2   EUCTR2016-004223-23-ES   France;Germany;Italy;Netherlands;Spain;United Kingdom;
      -   Phase 2   EUCTR2016-004223-23-FR   Canada;France;Italy;Netherlands;Spain;United Kingdom;United States;
   Swedish Orphan Biovitrum AG
      2017   Phase 2   EUCTR2016-004223-23-GB   Canada;France;Italy;Netherlands;Spain;United Kingdom;United States;
      -   Phase 2;Phase 3   EUCTR2021-001577-24-IT   Belgium;Canada;China;Czech Republic;Czechia;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
   Swedish Orphan Biovitrum AG (Sobi AG)
      2021   Phase 2;Phase 3   EUCTR2021-001577-24-PL   Belgium;Canada;China;Czechia;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2021   Phase 2;Phase 3   EUCTR2021-001577-24-ES   Belgium;Canada;China;Czechia;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
      -   Phase 2;Phase 3   EUCTR2021-001577-24-SE   Belgium;Canada;China;Czechia;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
      -   Phase 2;Phase 3   EUCTR2021-001577-24-FR   Belgium;Canada;China;Czechia;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
      -   Phase 2;Phase 3   EUCTR2021-001577-24-CZ   Belgium;Canada;China;Czech Republic;Czechia;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
NSAIDs   
   Hoffmann-La Roche
      2018   Phase 4   NCT03301883   China;
Naproxen   
   AstraZeneca
      2011   Phase 1   NCT01358383   United States;
   Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
      2009   Phase 4   NCT00807846   Chile;Costa Rica;Peru;Philippines;Russian Federation;Serbia;South Africa;Switzerland;Ukraine;United States;
Nicotinamide   
   UMC Utrecht
      -   Phase 1;Phase 2   EUCTR2016-003643-10-NL   Netherlands;
Non-Biologic DMARDs   
   Hoffmann-La Roche
      2000   -   NCT02784808   -
Non-steroidal anti-inflammatory drugs (NSAIDs)   
   Hoffmann-La Roche
      2008   Phase 3   NCT00642460   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;France;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
Norditropin SimpleXx 5mg/1.5ml   
   Royal Hospital For Sick Children, Yorkhill Division
      2004   -   EUCTR2004-004153-25-GB   United Kingdom;
NsNSAIDs   
   Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
      2009   -   NCT00688545   United States;
OLE BSA Adalimumab +/- MTX   
   Abbott
      2002   Phase 3   NCT00048542   Belgium;Czech Republic;France;Germany;Italy;Slovakia;Spain;United States;
OLE FD Adalimumab +/- MTX   
   Abbott
      2002   Phase 3   NCT00048542   Belgium;Czech Republic;France;Germany;Italy;Slovakia;Spain;United States;
OTEZLA - 10 MG + 20 MG + 30 MG COMPRESSA RIVESTITA CON FILM USO ORALE - BLISTER (PVC/ALU) IN UN ASTUCCIO - 4 COMPRESSE DA 10 MG + 4 COMPRESSE DA 20 MG +19 COMPRESSE DA   
   AMGEN INC.
      2021   Phase 3   EUCTR2019-002788-88-IT   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;
OTEZLA - 30 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (PVC/ALU) - 56 COMPRESSE   
   AMGEN INC.
      2021   Phase 3   EUCTR2019-002788-88-IT   Austria;Belgium;France;Germany;Italy;Netherlands;Spain;
Olumiant   
   ELI LILLY & COMPANY, LILLY CORPORATE CENTER
      2019   Phase 3   EUCTR2019-000119-10-IT   European Union;France;Germany;Italy;United Kingdom;
      2019   Phase 3   EUCTR2017-004518-24-IT   Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
   Eli Lilly and Company
      2020   Phase 3   EUCTR2019-000119-10-DE   France;Germany;Italy;Spain;United Kingdom;
      2019   Phase 3   EUCTR2019-000119-10-GB   France;Germany;United Kingdom;
      2019   Phase 3   EUCTR2019-000119-10-FR   France;Germany;United Kingdom;
      2019   Phase 3   EUCTR2017-004518-24-PL   Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
      2019   Phase 3   EUCTR2017-004518-24-GB   Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
      2019   Phase 3   EUCTR2017-004518-24-FR   Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
      2019   Phase 3   EUCTR2017-004518-24-DK   Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
      2019   Phase 3   EUCTR2017-004518-24-DE   Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
      2019   Phase 3   EUCTR2017-004518-24-CZ   Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
      2019   Phase 3   EUCTR2017-004518-24-BE   Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
      2019   Phase 3   EUCTR2017-004518-24-AT   Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
      2019   Phase 3   EUCTR2017-004495-60-PL   Argentina;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
      2019   Phase 3   EUCTR2017-004495-60-GB   Argentina;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
      2019   Phase 3   EUCTR2017-004495-60-FR   Argentina;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
      2019   Phase 3   EUCTR2017-004495-60-DK   Argentina;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
      2019   Phase 3   EUCTR2017-004471-31-PL   Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
      2019   Phase 3   EUCTR2017-004471-31-GB   Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
      2019   Phase 3   EUCTR2017-004471-31-FR   Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
      2019   Phase 3   EUCTR2017-004471-31-DK   Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
      2019   Phase 3   EUCTR2017-004471-31-DE   Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
      2019   Phase 3   EUCTR2017-004471-31-CZ   Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
      2019   Phase 3   EUCTR2017-004471-31-BE   Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
      -   Phase 3   EUCTR2017-004495-60-DE   Argentina;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
      -   Phase 3   EUCTR2017-004495-60-CZ   Argentina;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
      -   Phase 3   EUCTR2017-004495-60-BE   Argentina;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
      -   Phase 3   EUCTR2017-004495-60-AT   Argentina;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
      -   Phase 3   EUCTR2017-004471-31-AT   Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
   Lilly S.A.
      2019   Phase 3   EUCTR2017-004518-24-ES   Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
      2019   Phase 3   EUCTR2017-004471-31-ES   Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
Oluminant   
   ELI LILLY & COMPANY, LILLY CORPORATE CENTER
      2019   Phase 3   EUCTR2017-004518-24-IT   Argentina;Australia;Austria;Belgium;Brazil;China;Czech Republic;Czechia;Denmark;France;Germany;India;Israel;Italy;Japan;Mexico;Poland;Russian Federation;Spain;Turkey;United Kingdom;
Ondansetron   
   University of British Columbia
      2019   -   NCT04169828   Canada;
One Alpha Drops   
   Belfast Health and Social Care Trust, Musgrave Park Hospital
      2006   Phase 4   EUCTR2005-003129-23-GB   United Kingdom;
One-Alpha drops   
   Belfast Health and Social Care Trust, Musgrave Park Hospital
      2006   Phase 4   EUCTR2005-003129-23-GB   United Kingdom;
Orencia   
   University Medical Center Utrecht
      2014   -   EUCTR2013-003956-18-NL   Canada;Germany;Latvia;Netherlands;United States;
Originator adalimumab   
   FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO
      2021   Phase 4   EUCTR2021-004031-86-IT   Italy;
Otezla   
   Amgen Inc.
      2021   Phase 3   EUCTR2019-002788-88-NL   Austria;Belgium;France;Italy;Netherlands;
      2021   Phase 3   EUCTR2019-002788-88-FR   Austria;Belgium;France;Netherlands;
      -   Phase 3   EUCTR2019-002788-88-PL   Austria;Belgium;France;Italy;Netherlands;Poland;
      -   Phase 3   EUCTR2019-002788-88-BE   Austria;Belgium;Netherlands;
      -   Phase 3   EUCTR2019-002788-88-AT   Austria;Belgium;France;Italy;Netherlands;
Pneumo23   
   Institut National de la Santé Et de la Recherche Médicale, France
      2006   Phase 2/Phase 3   NCT00339157   France;
Profilassi per Herpes Zoster   
   Swedish Orphan Biovitrum AG
      -   Phase 2;Phase 3   EUCTR2021-001577-24-IT   Belgium;Canada;China;Czech Republic;Czechia;France;Germany;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;United Kingdom;United States;
Quadrivalent HPV vaccine   
   The University of New South Wales
      2007   Phase 3   NCT02263703   Australia;
RIL-1RA   
   University Medical Center Utrecht
      2016   Phase 4   EUCTR2015-004393-16-NL   Netherlands;
RO4877533   
   Roche Pharma AG
      2011   -   EUCTR2011-001097-25-DE   Germany;
RO4877533 (TCZ)   
   F. Hoffmann-La Roche Limited
      2008   -   EUCTR2007-000872-18-SK   Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2007-000872-18-SE   Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2007-000872-18-NL   Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2007-000872-18-ES   Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2007-000872-18-DK   Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
      -   Phase 3   EUCTR2007-000872-18-NO   Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Norway;Slovakia;Spain;Sweden;United Kingdom;
   F. Hoffmann-La Roche Ltd.
      2008   Phase 3   EUCTR2007-000872-18-GR   Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Norway;Slovakia;Spain;Sweden;United Kingdom;
      2008   Phase 3   EUCTR2007-000872-18-GB   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
      2008   -   EUCTR2007-000872-18-DE   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
      2008   -   EUCTR2007-000872-18-CZ   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
      2008   -   EUCTR2007-000872-18-BE   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
   ROCHE
      2008   -   EUCTR2007-000872-18-IT   Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
ROACTEMRA 20 mg/ml, concentrado para solución para perfusión   
   F. Hoffmann-La Roche Ltd
      2009   Phase 3   EUCTR2009-011593-15-ES   Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
RVG 104433   
   University Medical Center Utrecht
      2014   -   EUCTR2013-003956-18-NL   Canada;Germany;Latvia;Netherlands;United States;
RVG 28636   
   University Medical Center Utrecht
      2014   -   EUCTR2013-003956-18-NL   Canada;Germany;Latvia;Netherlands;United States;
Recombinant antihumanized anti-human monoclonal antibody directed against the IL-6R   
   F. Hoffmann-La Roche Ltd
      2013   Phase 1   EUCTR2012-003490-26-IT   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States;
      2013   Phase 1   EUCTR2012-003490-26-GB   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States;
      2013   Phase 1   EUCTR2012-003490-26-ES   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States;
      2013   Phase 1   EUCTR2012-003490-26-DE   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States;
      -   -   EUCTR2012-003490-26-Outside-EU/EEA   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States;
Recombinant human monoclonal antibody to human IL-1Beta of the IgG1/K class   
   Novartis Farmacéutica S.A.
      2009   Phase 3   EUCTR2008-005476-27-ES   Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Norway;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-008008-42-ES   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-005479-82-ES   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
   Novartis Pharma Services AG
      2010   -   EUCTR2008-008008-42-GR   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2008-005479-82-GR   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2008-005476-27-GR   Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
      2010   -   EUCTR2008-005476-27-GB   Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
      2009   Phase 3   EUCTR2008-005479-82-FR   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Norway;Spain;Sweden;United Kingdom;
      2009   Phase 3   EUCTR2008-005479-82-BE   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
      2009   Phase 3   EUCTR2008-005476-27-FR   Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Norway;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-008008-42-SE   Argentina;Austria;Belgium;Brazil;Canada;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Peru;Russian Federation;Spain;Swaziland;Sweden;Turkey;United Kingdom;United States;
      2009   -   EUCTR2008-008008-42-GB   Argentina;Austria;Belgium;Brazil;Canada;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Norway;Peru;Poland;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2009   -   EUCTR2008-008008-42-FR   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-008008-42-DK   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-008008-42-DE   Argentina;Austria;Belgium;Brazil;Canada;Denmark;France;Germany;Greece;Hungary;Israel;Italy;Netherlands;Norway;Peru;Poland;Russian Federation;Spain;Sweden;Switzerland;Turkey;United Kingdom;United States;
      2009   -   EUCTR2008-005479-82-SE   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-005479-82-HU   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-005479-82-GB   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-005479-82-DK   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-005479-82-DE   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-005479-82-AT   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-005476-27-SE   Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-005476-27-HU   Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-005476-27-DK   Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-005476-27-DE   Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
      2009   -   EUCTR2008-005476-27-BE   Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Spain;Sweden;United Kingdom;
      -   Phase 3   EUCTR2008-008008-42-NO   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom;
      -   Phase 3   EUCTR2008-005479-82-NO   Austria;Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Norway;Spain;Sweden;United Kingdom;
      -   Phase 3   EUCTR2008-005476-27-NO   Belgium;Denmark;France;Germany;Greece;Hungary;Italy;Norway;Spain;Sweden;United Kingdom;
Recombinant humanized anti-human monoclonal antibody directed against the IL-6R   
   F. Hoffmann-La Roche Ltd.
      2013   Phase 1   EUCTR2012-003486-18-PL   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
      2013   Phase 1   EUCTR2012-003486-18-IT   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
      2013   Phase 1   EUCTR2012-003486-18-GB   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
      2013   Phase 1   EUCTR2012-003486-18-ES   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
      2013   Phase 1   EUCTR2012-003486-18-DE   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
      -   -   EUCTR2012-003486-18-Outside-EU/EEA   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
Reumaflex   
   IRCCS Istituto Giannina Gaslini
      2019   Phase 3   EUCTR2018-001931-27-IT   Italy;
Rilonacept   
   Montefiore Medical Center
      2008   Phase 2   NCT00534495   United States;
Rilonacept (IL-1 Trap)   
   Regeneron Pharmaceuticals
      2005   Phase 1   NCT01803321   United States;
Ro 487-7533/F01   
   F. Hoffmann-La Roche Ltd
      2010   -   EUCTR2009-011593-15-NL   Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
      2009   Phase 3   EUCTR2009-011593-15-GB   Argentina;Australia;Belgium;Brazil;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
      2009   Phase 3   EUCTR2009-011593-15-BE   Argentina;Australia;Belgium;Brazil;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
      2009   -   EUCTR2009-011593-15-FR   Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
      2009   -   EUCTR2009-011593-15-DE   Argentina;Australia;Belgium;Brazil;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
Ro 487-7533/F10   
   University Hospitals Bristol NHS Foundation Trust
      2015   Phase 2   EUCTR2015-001323-23-GB   United Kingdom;
Ro 487-7533/F10-04   
   F. Hoffmann-La Roche Ltd
      2014   Phase 1   EUCTR2013-005212-98-IT   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Peru;Russian Federation;Spain;United Kingdom;United States;
      2014   Phase 1   EUCTR2013-005212-98-GB   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States;
      2014   Phase 1   EUCTR2013-005212-98-DE   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States;
      2013   Phase 1   EUCTR2012-003490-26-IT   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States;
      2013   Phase 1   EUCTR2012-003490-26-GB   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States;
      2013   Phase 1   EUCTR2012-003490-26-ES   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States;
      2013   Phase 1   EUCTR2012-003490-26-DE   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States;
      -   Phase 1   EUCTR2013-005212-98-FR   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Peru;Russian Federation;Spain;United Kingdom;United States;
      -   -   EUCTR2012-003490-26-Outside-EU/EEA   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States;
   F. Hoffmann-La Roche Ltd.
      2013   Phase 1   EUCTR2012-003486-18-PL   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
      2013   Phase 1   EUCTR2012-003486-18-IT   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
      2013   Phase 1   EUCTR2012-003486-18-GB   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
      2013   Phase 1   EUCTR2012-003486-18-ES   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
      2013   Phase 1   EUCTR2012-003486-18-DE   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
      -   -   EUCTR2012-003486-18-Outside-EU/EEA   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
   Roche Farma S.A. en nombre de F. Hoffmann-La Roche Ltd
      2014   -   EUCTR2013-005212-98-ES   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Peru;Russian Federation;Spain;United Kingdom;United States;
Ro-Actemra   
   Roche Pharma AG
      2011   -   EUCTR2011-001097-25-DE   Germany;
RoActemra   
   F. HOFFMANN - LA ROCHE LTD.
      2013   Phase 4   EUCTR2012-000444-10-IT   Australia;Canada;Germany;Italy;Mexico;Norway;Spain;Sweden;United Kingdom;
   F. Hoffmann-La Roche Ltd
      2014   Phase 1   EUCTR2013-005212-98-GB   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States;
      2014   Phase 1   EUCTR2013-005212-98-DE   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States;
      2013   Phase 1   EUCTR2012-003490-26-GB   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States;
      2013   Phase 1   EUCTR2012-003490-26-ES   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States;
      2013   Phase 1   EUCTR2012-003490-26-DE   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States;
      2010   -   EUCTR2009-011593-15-NL   Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
      2009   Phase 3   EUCTR2009-011593-15-GB   Argentina;Australia;Belgium;Brazil;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
      2009   Phase 3   EUCTR2009-011593-15-BE   Argentina;Australia;Belgium;Brazil;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
      2009   -   EUCTR2009-011593-15-IT   Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
      2009   -   EUCTR2009-011593-15-FR   Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
      2009   -   EUCTR2009-011593-15-DE   Argentina;Australia;Belgium;Brazil;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
   F. Hoffmann-La Roche Ltd.
      2013   Phase 1   EUCTR2012-003486-18-GB   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
      2013   Phase 1   EUCTR2012-003486-18-ES   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
      2013   Phase 1   EUCTR2012-003486-18-DE   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
      2012   Phase 4   EUCTR2012-000444-10-SE   Australia;Canada;Germany;Israel;Italy;Mexico;Norway;Russian Federation;Spain;Sweden;United Kingdom;
      2012   Phase 4   EUCTR2012-000444-10-GB   Australia;Canada;Germany;Israel;Italy;Mexico;Norway;Russian Federation;Spain;Sweden;United Kingdom;
      2012   Phase 4   EUCTR2012-000444-10-ES   Australia;Canada;Germany;Italy;Mexico;Norway;Spain;Sweden;United Kingdom;
      2012   Phase 4   EUCTR2012-000444-10-DE   Australia;Canada;Germany;Israel;Italy;Mexico;Norway;Russian Federation;Spain;Sweden;United Kingdom;
      2008   Phase 3   EUCTR2007-000872-18-GB   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
      2008   -   EUCTR2007-000872-18-DE   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
      2008   -   EUCTR2007-000872-18-CZ   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
      2008   -   EUCTR2007-000872-18-BE   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
      -   Phase 4   EUCTR2012-000444-10-NO   Australia;Canada;Germany;Italy;Mexico;Norway;Spain;Sweden;United Kingdom;
   Roche Farma S.A. en nombre de F. Hoffmann-La Roche Ltd
      2014   -   EUCTR2013-005212-98-ES   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Peru;Russian Federation;Spain;United Kingdom;United States;
   Roche Pharma AG
      2011   -   EUCTR2011-001097-25-DE   Germany;
   University Hospitals Bristol NHS Foundation Trust
      2015   Phase 2   EUCTR2015-001323-23-GB   United Kingdom;
RoActemra/Actemra (tocilizumab)   
   Hoffmann-La Roche
      2012   Phase 3   NCT01575769   Poland;Russian Federation;
SAR153191 (REGN88)   
   sanofi-aventis recherche & développement
      2021   Phase 2   EUCTR2015-004000-35-IE   Argentina;Bulgaria;Canada;Czech Republic;Czechia;Estonia;Finland;France;Germany;Ireland;Italy;Netherlands;Poland;Russian Federation;Spain;United Kingdom;
      2021   Phase 2   EUCTR2015-004000-35-BG   Argentina;Bulgaria;Canada;Czech Republic;Czechia;Estonia;Finland;France;Germany;Ireland;Italy;Netherlands;Poland;Russian Federation;Spain;United Kingdom;
      2017   Phase 2   EUCTR2015-004000-35-PL   Argentina;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
      2017   Phase 2   EUCTR2015-004000-35-NL   Argentina;Brazil;Bulgaria;Canada;Chile;Czech Republic;Czechia;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
      2017   Phase 2   EUCTR2015-004000-35-GB   Argentina;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
      2017   Phase 2   EUCTR2015-004000-35-DE   Argentina;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
      2017   Phase 2   EUCTR2015-003999-79-DE   Argentina;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
      2016   Phase 2   EUCTR2015-004000-35-IT   Argentina;Brazil;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
      2016   Phase 2   EUCTR2015-004000-35-FI   Argentina;Bulgaria;Canada;Chile;Czech Republic;Czechia;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
      2016   Phase 2   EUCTR2015-004000-35-ES   Argentina;Brazil;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
      2016   Phase 2   EUCTR2015-004000-35-EE   Argentina;Brazil;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
      2016   Phase 2   EUCTR2015-003999-79-PL   Argentina;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
      2016   Phase 2   EUCTR2015-003999-79-NL   Argentina;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
      2016   Phase 2   EUCTR2015-003999-79-IT   Argentina;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
      2016   Phase 2   EUCTR2015-003999-79-FI   Argentina;Canada;Chile;Czech Republic;Czechia;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
      2016   Phase 2   EUCTR2015-003999-79-ES   Argentina;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
      2016   Phase 2   EUCTR2015-003999-79-CZ   Argentina;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
      -   Phase 2   EUCTR2015-004000-35-FR   Argentina;Brazil;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
      -   Phase 2   EUCTR2015-004000-35-CZ   Argentina;Bulgaria;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
      -   Phase 2   EUCTR2015-003999-79-GB   Argentina;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
      -   Phase 2   EUCTR2015-003999-79-FR   Argentina;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
      -   Phase 2   EUCTR2015-003999-79-EE   Argentina;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
      -   -   EUCTR2015-003999-79-Outside-EU/EEA   Argentina;Canada;Chile;Czech Republic;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
SB4 (etanercept biosimilar)   
   Samsung Bioepis Co., Ltd.
      2013   Phase 3   EUCTR2012-005026-30-HU   Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
      2013   -   EUCTR2012-005026-30-PL   Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
      2013   -   EUCTR2012-005026-30-CZ   Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
      2013   -   EUCTR2012-005026-30-BG   Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
SB5   
   Samsung Bioepis Co., Ltd
      2015   -   EUCTR2014-004887-39-PL   Poland;
   Samsung Bioepis Co., Ltd.
      2014   Phase 3   EUCTR2013-005013-13-BG   Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom;
      2014   -   EUCTR2013-005013-13-PL   Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Latvia;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom;
      2014   -   EUCTR2013-005013-13-LT   Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom;
      2014   -   EUCTR2013-005013-13-CZ   Bosnia and Herzegovina;Bulgaria;Czech Republic;Korea, Republic of;Lithuania;Mexico;Poland;Russian Federation;Ukraine;United Kingdom;
SSGJ-613   
   Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
      2021   Phase 1   NCT05027373   China;
SUB180983   
   ELI LILLY & COMPANY, LILLY CORPORATE CENTER
      2019   Phase 3   EUCTR2019-000119-10-IT   European Union;France;Germany;Italy;United Kingdom;
Sarilumab   
   Sanofi
      2016   Phase 2   NCT02776735   Argentina;Canada;Chile;Czech Republic;Czechia;Estonia;Finland;France;Germany;Italy;Mexico;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
Sarilumab SAR153191 (REGN88)   
   Sanofi
      2018   Phase 2   NCT02991469   Argentina;Bulgaria;Canada;Chile;Czechia;Estonia;Finland;France;Germany;Ireland;Italy;Netherlands;Poland;Russian Federation;Spain;United Kingdom;United States;
Sedatives/Hypnotics,Other   
   University of Oulu
      2017   Phase 4   NCT03069638   Finland;
Somatropin   
   Royal Hospital For Sick Children, Yorkhill Division
      2004   -   EUCTR2004-004153-25-GB   United Kingdom;
Sulfasalazine   
   Pfizer
      2010   Phase 4   NCT00637780   Canada;Mexico;United States;
TC-MSC   
   University Medical Center Utrecht
      2014   -   EUCTR2012-002067-10-NL   Netherlands;
TNFR:Fc   
   Samsung Bioepis Co., Ltd.
      2013   Phase 3   EUCTR2012-005026-30-HU   Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
      2013   -   EUCTR2012-005026-30-PL   Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
      2013   -   EUCTR2012-005026-30-CZ   Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
      2013   -   EUCTR2012-005026-30-BG   Bulgaria;Colombia;Czech Republic;Hungary;India;Korea, Republic of;Lithuania;Mexico;Poland;Ukraine;United Kingdom;
TRIAMCINOLONE HEXACETONIDE   
   Oslo University Hospital
      2020   Phase 4   EUCTR2019-000889-38-NO   Norway;
Taltz (80 mg solution for injection in pre-filled syringe)   
   ELI LILLY & COMPANY, LILLY CORPORATE CENTER
      2020   Phase 3   EUCTR2018-000681-10-IT   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
   Eli Lilly and Company
      2021   Phase 3   EUCTR2018-000681-10-CZ   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
      2020   Phase 3   EUCTR2018-000681-10-GB   Belgium;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
      2020   Phase 3   EUCTR2018-000681-10-DK   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
      2020   Phase 3   EUCTR2018-000681-10-DE   Belgium;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
      -   Phase 3   EUCTR2018-000681-10-NL   Belgium;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
      -   Phase 3   EUCTR2018-000681-10-FR   Belgium;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
      -   Phase 3   EUCTR2018-000681-10-BE   Belgium;Czech Republic;Denmark;France;Germany;Italy;Netherlands;Spain;Switzerland;United Kingdom;
Tocilizumab   
    Clinical Immunology, Jichi Medical University
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2016   Phase 3   EUCTR2016-000312-15-FR   France;
   Assistance Publique - Hôpitaux de Paris
      2017   Phase 3   NCT02840175   France;
   Children's Hospital of Chongqing Medical University
      2017   -   ChiCTR-OPB-17013704   China;
      2016   -   ChiCTR-OPC-17011391   China;
   Division of Rheumatology &
   Eric B. Suhler
      2013   Phase 1/Phase 2   NCT01603355   United States;
   F. Hoffmann-La Roche Limited
      2008   -   EUCTR2007-000872-18-SK   Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2007-000872-18-DK   Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
   F. Hoffmann-La Roche Ltd
      2015   Phase 1   EUCTR2015-000435-33-PL   Belgium;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom;
      2015   Phase 1   EUCTR2015-000435-33-HU   Belgium;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom;
      2015   Phase 1   EUCTR2015-000435-33-GB   Belgium;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom;
      2015   Phase 1   EUCTR2015-000435-33-DE   Belgium;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom;
      2015   Phase 1   EUCTR2015-000435-33-BE   Belgium;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom;
      2010   -   EUCTR2009-011593-15-NL   Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
      2009   Phase 3   EUCTR2009-011593-15-GB   Argentina;Australia;Belgium;Brazil;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
      2009   Phase 3   EUCTR2009-011593-15-BE   Argentina;Australia;Belgium;Brazil;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
      2009   -   EUCTR2009-011593-15-FR   Belgium;France;Germany;Italy;Netherlands;Spain;United Kingdom;
      2009   -   EUCTR2009-011593-15-DE   Argentina;Australia;Belgium;Brazil;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
      -   Phase 1   EUCTR2015-000435-33-FR   Argentina;Belgium;Canada;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom;United States;
   F. Hoffmann-La Roche Ltd.
      2012   Phase 4   EUCTR2012-000444-10-SE   Australia;Canada;Germany;Israel;Italy;Mexico;Norway;Russian Federation;Spain;Sweden;United Kingdom;
      2012   Phase 4   EUCTR2012-000444-10-GB   Australia;Canada;Germany;Israel;Italy;Mexico;Norway;Russian Federation;Spain;Sweden;United Kingdom;
      2012   Phase 4   EUCTR2012-000444-10-ES   Australia;Canada;Germany;Italy;Mexico;Norway;Spain;Sweden;United Kingdom;
      2012   Phase 4   EUCTR2012-000444-10-DE   Australia;Canada;Germany;Israel;Italy;Mexico;Norway;Russian Federation;Spain;Sweden;United Kingdom;
      2008   Phase 3   EUCTR2007-000872-18-GB   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
      2008   -   EUCTR2007-000872-18-DE   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
      2008   -   EUCTR2007-000872-18-CZ   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
      2008   -   EUCTR2007-000872-18-BE   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
      -   Phase 4   EUCTR2012-000444-10-NO   Australia;Canada;Germany;Italy;Mexico;Norway;Spain;Sweden;United Kingdom;
   Hoffmann-La Roche
      2018   Phase 4   NCT03301883   China;
      2014   Phase 1   NCT02165345   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States;
      2013   Phase 4   NCT01734382   Argentina;Australia;Canada;Germany;Israel;Italy;Mexico;Norway;Russian Federation;Spain;Sweden;United Kingdom;United States;
      2013   Phase 1   NCT01904292   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States;
      2013   Phase 1   NCT01904279   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
      2012   Phase 1   NCT01455701   Argentina;Belgium;Canada;France;Germany;Hungary;Poland;Russian Federation;Spain;United Kingdom;United States;
      2009   Phase 3   NCT00988221   Argentina;Australia;Belgium;Brazil;Canada;France;Germany;Italy;Mexico;Netherlands;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
   ROCHE
      2008   -   EUCTR2007-000872-18-IT   Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
   Roche Farma S.A en nombre de F. Hoffmann-La Roche Ltd
      2015   Phase 1   EUCTR2015-000435-33-ES   Belgium;France;Germany;Hungary;Italy;Poland;Russian Federation;Spain;United Kingdom;
   Shenzhen Children's Hospital
      2017   -   ChiCTR-INR-17011829   China;
   Tufts Medical Center
      2009   -   NCT00868751   United States;
   University Hospitals Bristol NHS Foundation Trust
      2015   Phase 2   EUCTR2015-001323-23-GB   United Kingdom;
   University of Oklahoma
      2009   -   NCT00862758   United States;
   Yokohama City University Hospital Department of Pediatrics
      2016   -   JPRN-UMIN000024178   Japan;
Tocilizumab Roche   
   F. Hoffmann-La Roche Limited
      2008   -   EUCTR2007-000872-18-SE   Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2007-000872-18-NL   Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
      2008   -   EUCTR2007-000872-18-ES   Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Slovakia;Spain;Sweden;United Kingdom;
      -   Phase 3   EUCTR2007-000872-18-NO   Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Norway;Slovakia;Spain;Sweden;United Kingdom;
   F. Hoffmann-La Roche Ltd.
      2008   Phase 3   EUCTR2007-000872-18-GR   Belgium;Czech Republic;Denmark;Germany;Greece;Italy;Netherlands;Norway;Slovakia;Spain;Sweden;United Kingdom;
Tocilizumab SC   
   F. Hoffmann-La Roche Ltd
      2014   Phase 1   EUCTR2013-005212-98-GB   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States;
      2014   Phase 1   EUCTR2013-005212-98-DE   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States;
      2013   Phase 1   EUCTR2012-003490-26-IT   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States;
      2013   Phase 1   EUCTR2012-003490-26-GB   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States;
      2013   Phase 1   EUCTR2012-003490-26-ES   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States;
      2013   Phase 1   EUCTR2012-003490-26-DE   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States;
      -   -   EUCTR2012-003490-26-Outside-EU/EEA   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Mexico;Russian Federation;Spain;United Kingdom;United States;
   F. Hoffmann-La Roche Ltd.
      2013   Phase 1   EUCTR2012-003486-18-PL   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
      2013   Phase 1   EUCTR2012-003486-18-IT   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
      2013   Phase 1   EUCTR2012-003486-18-GB   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
      2013   Phase 1   EUCTR2012-003486-18-ES   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
      2013   Phase 1   EUCTR2012-003486-18-DE   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
      -   -   EUCTR2012-003486-18-Outside-EU/EEA   Argentina;Australia;Brazil;Canada;France;Germany;Italy;Peru;Poland;Russian Federation;Spain;United Kingdom;United States;
Tocilizumab [RoActemra/Actemra]   
   Hoffmann-La Roche
      2013   Phase 3   NCT01727986   Brazil;
      2012   Phase 3   NCT01673919   France;
      2012   Phase 3   NCT01667471   Germany;
      2008   Phase 3   NCT00642460   Argentina;Australia;Belgium;Brazil;Canada;Czech Republic;Denmark;France;Germany;Greece;Italy;Mexico;Netherlands;Norway;Poland;Slovakia;Spain;Sweden;United Kingdom;United States;
Tofacitinib   
   PFIZER INC.
      2013   -   EUCTR2011-004915-22-IT   Argentina;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;
      2012   -   EUCTR2011-004914-40-IT   Argentina;Hungary;Italy;Mexico;Poland;Russian Federation;
   Pfizer
      2013   Phase 3   NCT01500551   Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Costa Rica;Germany;Hungary;Israel;Mexico;Poland;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Turkey;Ukraine;United Kingdom;United States;
   Pfizer Inc
      2012   Phase 2;Phase 3   EUCTR2011-004915-22-SK   Argentina;Australia;Belgium;Brazil;Canada;China;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
   Pfizer Inc, 235 East 42nd Street, New York, NY 10017
      2012   Phase 1   EUCTR2011-004914-40-HU   Argentina;Czech Republic;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;Serbia;Slovakia;
      2012   -   EUCTR2011-004914-40-SK   Argentina;Czech Republic;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;Serbia;Slovakia;
      2012   -   EUCTR2011-004914-40-PL   Argentina;Czech Republic;Germany;Hungary;Italy;Mexico;Poland;Russian Federation;Serbia;Slovakia;
   Pfizer Inc, 235 East 42nd Street, New York, New York 10017
      2018   Phase 2;Phase 3   EUCTR2011-004915-22-BE   Argentina;Australia;Belgium;Brazil;Canada;China;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2012   Phase 2;Phase 3   EUCTR2011-004915-22-PL   Argentina;Australia;Belgium;Bosnia and Herzegovina;Brazil;Canada;Chile;Colombia;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2012   Phase 2;Phase 3   EUCTR2011-004915-22-DE   Argentina;Australia;Belgium;Brazil;Canada;Chile;Germany;Hungary;Israel;Italy;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
      2012   -   EUCTR2011-004915-22-HU   Czech Republic;Germany;Hungary;Italy;Poland;Russian Federation;Serbia;Slovakia;
      -   Phase 2;Phase 3   EUCTR2011-004915-22-NL   Argentina;Australia;Belgium;Brazil;Canada;Chile;China;Costa Rica;Germany;Hungary;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Turkey;Ukraine;United Kingdom;United States;
   Pfizer Inc.
      2018   Phase 2;Phase 3   EUCTR2011-004915-22-GB   Argentina;Australia;Belgium;Brazil;Canada;Chile;Germany;Hungary;Israel;Italy;Mexico;New Zealand;Peru;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;Switzerland;Taiwan;Turkey;Ukraine;United Kingdom;United States;
Tofacitinib citrate   
   PFIZER INC
      2020   Phase 3   EUCTR2017-002018-29-IT   Argentina;Belgium;Brazil;Canada;Chile;China;Germany;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
   Pfizer Inc, 235 East 42nd Street, New York, New York 10017
      -   Phase 2;Phase 3   EUCTR2011-004915-22-SE   Argentina;Australia;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
Tofacitinibe citrate   
   Pfizer Inc
      2012   Phase 2;Phase 3   EUCTR2011-004915-22-SK   Argentina;Australia;Belgium;Brazil;Canada;China;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
   Pfizer Inc, 235 East 42nd Street, New York, New York 10017
      2018   Phase 2;Phase 3   EUCTR2011-004915-22-BE   Argentina;Australia;Belgium;Brazil;Canada;China;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;New Zealand;Peru;Philippines;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Taiwan;Turkey;Ukraine;United Kingdom;United States;
   Pfizer Inc.
      2020   Phase 3   EUCTR2017-002018-29-SK   Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
   Pfizer Inc. 235 East 42nd Street, New York, New York 10017
      2022   Phase 3   EUCTR2017-002018-29-HU   Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2017-002018-29-NL   Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2021   Phase 3   EUCTR2017-002018-29-DE   Argentina;Belgium;Brazil;Canada;Chile;China;Eritrea;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      2020   Phase 3   EUCTR2017-002018-29-PL   Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      -   Phase 3   EUCTR2017-002018-29-SE   Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
      -   Phase 3   EUCTR2017-002018-29-BE   Argentina;Belgium;Brazil;Canada;China;Costa Rica;Germany;Hungary;India;Israel;Italy;Mexico;Netherlands;Poland;Russian Federation;Slovakia;South Africa;Spain;Sweden;Turkey;Ukraine;United Kingdom;United States;
Triamcinolone Hexacetonide 20 MG/ML   
   Oslo University Hospital
      2020   Phase 4   NCT04614311   Norway;
Upadacitinib   
   ABBVIE DEUTSCHLAND GMBH & CO. KG
      2019   Phase 1   EUCTR2018-000715-25-IT   Germany;Hungary;Italy;Spain;United States;
   AbbVie
      2019   Phase 1   NCT03725007   Germany;Hungary;Israel;Italy;Puerto Rico;Spain;United States;
   AbbVie Deutschland GmbH & Co. KG
      2019   Phase 1;Phase 3   EUCTR2018-000715-25-ES   Germany;Hungary;Italy;Spain;United States;
      2019   Phase 1   EUCTR2018-000715-25-HU   Germany;Hungary;Italy;Spain;United States;
      2019   Phase 1   EUCTR2018-000715-25-DE   Germany;Hungary;Italy;Spain;United States;
VIMOVO 250/20   
   Horizon Pharma Ireland, Ltd., Dublin Ireland
      2012   Phase 4   NCT01544114   United States;
VIMOVO 375/20   
   Horizon Pharma Ireland, Ltd., Dublin Ireland
      2012   Phase 4   NCT01544114   United States;
VIMOVO 500/20   
   Horizon Pharma Ireland, Ltd., Dublin Ireland
      2012   Phase 4   NCT01544114   United States;
VSL#3   
   Assistance Publique - Hôpitaux de Paris
      2017   -   NCT03092427   France;
Vitamin B3   
   UMC Utrecht
      2019   Phase 1;Phase 2   EUCTR2018-002245-11-NL   Netherlands;
Yellow Fever vaccine (17D)   
   University of Sao Paulo General Hospital
      2018   -   NCT03430388   Brazil;
ibuprofen/26.6 mg famotidine   
   Horizon Pharma Ireland, Ltd., Dublin Ireland
      2012   Phase 4   NCT01563185   United States;